The	O
translesion	B-protein
DNA	I-protein
polymerase	I-protein
zeta	I-protein
plays	O
a	O
major	O
role	O
in	O
Ig	O
and	O
bcl-6	O
somatic	O
hypermutation	O
.	O

Ig	O
somatic	O
mutations	O
would	O
be	O
introduced	O
by	O
a	O
polymerase	B-protein
(	O
pol	B-protein
)	O
while	O
repairing	O
DNA	O
outside	O
main	O
DNA	O
replication	O
.	O

We	O
show	O
that	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
constitutively	O
express	O
the	O
translesion	B-protein
pol	I-protein
zeta	I-protein
,	O
which	O
effectively	O
extends	O
DNA	O
past	O
mismatched	O
bases	O
(	O
mispair	O
extender	O
)	O
,	O
and	O
pol	B-protein
eta	I-protein
,	O
which	O
bypasses	O
DNA	O
lesions	O
in	O
an	O
error-free	O
fashion	O
.	O

Upon	O
B	B-protein
cell	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
engagement	O
and	O
coculture	O
with	O
activated	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
these	O
lymphocytes	B-cell_type
upregulated	O
pol	B-protein
zeta	I-protein
,	O
downregulated	O
pol	B-protein
eta	I-protein
,	O
and	O
mutated	O
the	O
Ig	B-DNA
and	I-DNA
bcl-6	I-DNA
genes	I-DNA
.	O

Inhibition	O
of	O
the	O
pol	B-protein
zeta	I-protein
REV3	B-protein
catalytic	I-protein
subunit	I-protein
by	O
specific	O
phosphorothioate-modified	O
oligonucleotides	O
impaired	O
Ig	O
and	O
bcl-6	O
hypermutation	O
and	O
UV	O
damage-induced	O
DNA	O
mutagenesis	O
,	O
without	O
affecting	O
cell	O
cycle	O
or	O
viability	O
.	O

Thus	O
,	O
pol	B-protein
zeta	I-protein
plays	O
a	O
critical	O
role	O
in	O
Ig	O
and	O
bcl-6	O
hypermutation	O
,	O
perhaps	O
facilitated	O
by	O
the	O
downregulation	O
of	O
pol	B-protein
eta	I-protein
.	O

iduosnuep	NULL
1oyny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
+	NULL
4	NULL
,	NULL
%	NULL
,	NULL
vic	NULL
``	NULL
``	NULL
~	NULL
-	NULL
HHS	NULL
Public	NULL
Access	NULL
Fa	NULL
Author	NULL
manuscript	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04	NULL
.	NULL

Published	NULL
in	NULL
final	NULL
edited	NULL
form	NULL
as	NULL
:	NULL
Immunity	NULL
.	NULL

2001	NULL
May	NULL
;	NULL
14	NULL
(	NULL
53	NULL
)	NULL
:	NULL
643-653	NULL
.	NULL

The	NULL
Translesion	NULL
DNA	NULL
Polymerase	NULL
C	NULL
Plays	NULL
a	NULL
Major	NULL
Role	NULL
in	NULL
Ig	NULL
and	NULL
bel-6	NULL
Somatic	NULL
Hypermutation	NULL
Hong	NULL
Zan	NULL
'	NULL
,	NULL
Atsumasa	NULL
Komori	NULL
'	NULL
,	NULL
Zongdong	NULL
Li	NULL
'	NULL
,	NULL
Andrea	NULL
Cerutti	NULL
'	NULL
,	NULL
Andras	NULL
Schaffer	NULL
,	NULL
Martin	NULL
F.	NULL
Flajnik*	NULL
,	NULL
Marilyn	NULL
Diaz	NULL
``	NULL
,	NULL
and	NULL
Paolo	NULL
Casali	NULL
'	NULL
2	NULL
%	NULL
:5	NULL
1	NULL
Divigion	NULL
of	NULL
Molecular	NULL
Immunology	NULL
,	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
New	NULL
York	NULL
,	NULL
New	NULL
York	NULL
10021	NULL
2	NULL
?	NULL

Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
Cornell	NULL
University	NULL
Weill	NULL
Medical	NULL
College	NULL
,	NULL
New	NULL
York	NULL
,	NULL
New	NULL
York	NULL
10021	NULL
Immunology	NULL
Program	NULL
,	NULL
Cornell	NULL
University	NULL
Weill	NULL
Graduate	NULL
School	NULL
of	NULL
Medical	NULL
Sciences	NULL
,	NULL
New	NULL
York	NULL
,	NULL
New	NULL
York	NULL
10021	NULL
*	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
University	NULL
of	NULL
Maryland	NULL
,	NULL
Baltimore	NULL
,	NULL
Maryland	NULL
21201	NULL
5	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
The	NULL
Scripps	NULL
Research	NULL
Institute	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
California	NULL
92037	NULL
Summary	NULL
Ig	NULL
somatic	NULL
mutations	NULL
would	NULL
be	NULL
introduced	NULL
by	NULL
a	NULL
polymerase	NULL
(	NULL
pol	NULL
)	NULL
while	NULL
repairing	NULL
DNA	NULL
outside	NULL
main	NULL
DNA	NULL
replication	NULL
.	NULL

We	NULL
show	NULL
that	NULL
human	NULL
B	NULL
cells	NULL
constitutively	NULL
express	NULL
the	NULL
translesion	NULL
pol	NULL
&	NULL
,	NULL
which	NULL
effectively	NULL
extends	NULL
DNA	NULL
past	NULL
mismatched	NULL
bases	NULL
(	NULL
mispair	NULL
extender	NULL
)	NULL
,	NULL
and	NULL
pol	NULL
n	NULL
,	NULL
which	NULL
bypasses	NULL
DNA	NULL
lesions	NULL
in	NULL
an	NULL
error-free	NULL
fashion	NULL
.	NULL

Upon	NULL
B	NULL
cell	NULL
receptor	NULL
(	NULL
BCR	NULL
)	NULL
engagement	NULL
and	NULL
coculture	NULL
with	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
these	NULL
lymphocytes	NULL
upregulated	NULL
pol	NULL
£	NULL
,	NULL
downregulated	NULL
pol	NULL
1	NULL
,	NULL
and	NULL
mu	NULL
tated	NULL
the	NULL
Ig	NULL
and	NULL
be/-6	NULL
genes	NULL
.	NULL

Inhibition	NULL
of	NULL
the	NULL
pol	NULL
£	NULL
REV3	NULL
catalytic	NULL
subunit	NULL
by	NULL
specific	NULL
phosphorothioate-modified	NULL
oligonucleotides	NULL
impaired	NULL
Ig	NULL
and	NULL
be/-6	NULL
hypermutation	NULL
and	NULL
UV	NULL
damage-induced	NULL
DNA	NULL
mutagenesis	NULL
,	NULL
without	NULL
affecting	NULL
cell	NULL
cycle	NULL
or	NULL
viability	NULL
.	NULL

Thus	NULL
,	NULL
pol	NULL
&	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
Ig	NULL
and	NULL
be/-6	NULL
hypermutation	NULL
,	NULL
perhaps	NULL
facilitated	NULL
by	NULL
the	NULL
downregulation	NULL
of	NULL
pol	NULL
.	NULL

Introduction	NULL
Somatic	NULL
hypermutation	NULL
underlies	NULL
the	NULL
affinity	NULL
maturation	NULL
of	NULL
the	NULL
antibody	NULL
response	NULL
(	NULL
McKean	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
;	NULL
Ueki	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Ikematsu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Chang	NULL
and	NULL
Casali	NULL
,	NULL
1994	NULL
;	NULL
Ikematsu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Neuberger	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

It	NULL
targets	NULL
both	NULL
the	NULL
Ig	NULL
and	NULL
the	NULL
be/-6	NULL
loci	NULL
and	NULL
introduces	NULL
single	NULL
base	NULL
substitutions	NULL
,	NULL
with	NULL
rare	NULL
deletions	NULL
or	NULL
insertions	NULL
(	NULL
Pasqualuceci	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Shen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
,	NULL
2000a	NULL
)	NULL
.	NULL

Somatic	NULL
Ig	NULL
and	NULL
be/-6	NULL
point	NULL
mutations	NULL
accumulate	NULL
at	NULL
a	NULL
rate	NULL
of	NULL
107	NULL
to	NULL
10~*	NULL
per	NULL
base	NULL
per	NULL
cell	NULL
generation	NULL
and	NULL
extend	NULL
1.5-2.0	NULL
kb	NULL
downstream	NULL
of	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
,	NULL
with	NULL
preference	NULL
for	NULL
certain	NULL
hot	NULL
spots	NULL
(	NULL
Peters	NULL
and	NULL
Storb	NULL
,	NULL
1996	NULL
;	NULL
Fukita	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Neuberger	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Shen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Storb	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998a	NULL
;	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
,	NULL
2000a	NULL
)	NULL
.	NULL

They	NULL
favor	NULL
transitions	NULL
over	NULL
transversions	NULL
and	NULL
display	NULL
strand	NULL
polarity	NULL
,	NULL
as	NULL
inferred	NULL
from	NULL
the	NULL
A	NULL
over	NULL
T	NULL
bias	NULL
in	NULL
murine	NULL
Ig	NULL
gene	NULL
V	NULL
sequences	NULL
(	NULL
Smith	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
8	NULL
Correspondence	NULL
:	NULL
peasali	NULL
@	NULL
med.cornell.edu	NULL
.	NULL

iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
2	NULL
Neuberger	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Storb	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998a	NULL
)	NULL
and	NULL
G	NULL
over	NULL
C	NULL
bias	NULL
in	NULL
human	NULL
Ig	NULL
V	NULL
(	NULL
D	NULL
)	NULL
J	NULL
and	NULL
be/-6	NULL
sequences	NULL
(	NULL
Chang	NULL
and	NULL
Casali	NULL
,	NULL
1994	NULL
;	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
,	NULL
20002	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
that	NULL
underlies	NULL
somatic	NULL
hypermutation	NULL
remains	NULL
speculative	NULL
,	NULL
but	NULL
DNA	NULL
breaks	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
Ig	NULL
V	NULL
(	NULL
D	NULL
)	NULL
J	NULL
DNA	NULL
regions	NULL
of	NULL
hypermutating	NULL
B	NULL
cells	NULL
,	NULL
suggesting	NULL
a	NULL
role	NULL
of	NULL
these	NULL
lesions	NULL
in	NULL
hypermutation	NULL
(	NULL
Sale	NULL
and	NULL
Neuberger	NULL
,	NULL
1998	NULL
;	NULL
Bross	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
;	NULL
Papavasiliou	NULL
and	NULL
Schatz	NULL
,	NULL
2000	NULL
)	NULL
.	NULL

Mutations	NULL
would	NULL
be	NULL
introduced	NULL
as	NULL
mismatched	NULL
nucleotides	NULL
by	NULL
a	NULL
DNA	NULL
polymerase	NULL
while	NULL
repairing	NULL
a	NULL
single-strand	NULL
DNA	NULL
gap	NULL
(	NULL
Bertocci	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Diaz	NULL
and	NULL
Flajnik	NULL
,	NULL
1998	NULL
;	NULL
Storb	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998b	NULL
;	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000b	NULL
)	NULL
or	NULL
double-strand	NULL
DNA	NULL
breaks	NULL
(	NULL
DSBs	NULL
)	NULL
through	NULL
homologous	NULL
recombination	NULL
,	NULL
possibly	NULL
in	NULL
concert	NULL
with	NULL
another	NULL
polymerase	NULL
(	NULL
s	NULL
)	NULL
,	NULL
with	NULL
low	NULL
processivity	NULL
and	NULL
error	NULL
prone	NULL
(	NULL
Papavasiliou	NULL
and	NULL
Schatz	NULL
,	NULL
2000	NULL
;	NULL
Poltoratsky	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

After	NULL
their	NULL
introduction	NULL
,	NULL
the	NULL
mutations	NULL
would	NULL
be	NULL
``	NULL
fixed	NULL
``	NULL
by	NULL
the	NULL
cellular	NULL
mismatch	NULL
repair	NULL
complex	NULL
and	NULL
passed	NULL
on	NULL
to	NULL
the	NULL
progeny	NULL
B	NULL
cells	NULL
(	NULL
Rada	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Shannon	NULL
and	NULL
Weigert	NULL
,	NULL
1998	NULL
)	NULL
.	NULL

Knowledge	NULL
of	NULL
DNA	NULL
synthesis	NULL
and	NULL
repair	NULL
in	NULL
eukaryotes	NULL
has	NULL
increased	NULL
considerably	NULL
,	NULL
leading	NULL
to	NULL
the	NULL
identification	NULL
of	NULL
a	NULL
dozen	NULL
DNA	NULL
polymerases	NULL
.	NULL

Pol	NULL
a	NULL
,	NULL
8	NULL
,	NULL
and	NULL
&	NULL
are	NULL
involved	NULL
mainly	NULL
in	NULL
DNA	NULL
replication	NULL
and	NULL
are	NULL
expressed	NULL
prevalently	NULL
in	NULL
the	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
Burgers	NULL
,	NULL
1998	NULL
)	NULL
.	NULL

Pol	NULL
y	NULL
specifically	NULL
replicates	NULL
mitochondrial	NULL
DNA	NULL
(	NULL
Weissbach	NULL
,	NULL
1979	NULL
)	NULL
,	NULL
and	NULL
pol	NULL
6	NULL
is	NULL
restricted	NULL
to	NULL
DNA	NULL
interstrand	NULL
crosslink	NULL
repair	NULL
(	NULL
Johnson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000a	NULL
)	NULL
.	NULL

Because	NULL
of	NULL
their	NULL
specialized	NULL
function	NULL
,	NULL
these	NULL
DNA	NULL
polymerases	NULL
are	NULL
unlikely	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
hypermutation	NULL
process	NULL
.	NULL

Pol	NULL
B	NULL
is	NULL
essential	NULL
for	NULL
base	NULL
excision	NULL
repair	NULL
and	NULL
is	NULL
error	NULL
prone	NULL
(	NULL
Prasad	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Sobol	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
but	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
hypermutation	NULL
,	NULL
as	NULL
immune-incompetent	NULL
mice	NULL
reconstituted	NULL
with	NULL
pol	NULL
B-deficient	NULL
fetal	NULL
liver	NULL
cells	NULL
mutate	NULL
their	NULL
Ig	NULL
genes	NULL
normally	NULL
upon	NULL
antigenic	NULL
challenge	NULL
(	NULL
Esposito	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000b	NULL
)	NULL
.	NULL

Both	NULL
pol	NULL
&	NULL
and	NULL
pol	NULL
n	NULL
(	NULL
Rad30A	NULL
)	NULL
are	NULL
efficient	NULL
translesion	NULL
polymerases	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
they	NULL
carry	NULL
out	NULL
lesion	NULL
bypass	NULL
DNA	NULL
synthesis	NULL
)	NULL
and	NULL
could	NULL
be	NULL
involved	NULL
in	NULL
hypermutation	NULL
.	NULL

Pol	NULL
{	NULL
is	NULL
responsible	NULL
for	NULL
most	NULL
damage-induced	NULL
and	NULL
spontaneous	NULL
DNA	NULL
mutagenesis	NULL
(	NULL
mutagenic	NULL
DNA	NULL
repair	NULL
)	NULL
(	NULL
Morrison	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Lawrence	NULL
and	NULL
Hinkle	NULL
,	NULL
1996	NULL
;	NULL
Nelson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Holbeck	NULL
and	NULL
Strathern	NULL
,	NULL
1997	NULL
;	NULL
Gibbs	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
,	NULL
2000	NULL
;	NULL
Lin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
;	NULL
Murakumo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
,	NULL
and	NULL
pol	NULL
1	NULL
is	NULL
the	NULL
defective	NULL
polymerase	NULL
in	NULL
patients	NULL
with	NULL
the	NULL
variant	NULL
form	NULL
of	NULL
Xeroderma	NULL
pigmentosum	NULL
(	NULL
XP-V	NULL
)	NULL
(	NULL
Johnson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999b	NULL
;	NULL
Masutani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999b	NULL
)	NULL
.	NULL

In	NULL
spite	NULL
of	NULL
its	NULL
highly	NULL
distributive	NULL
nature	NULL
and	NULL
intrinsic	NULL
lack	NULL
of	NULL
proofreading	NULL
capacity	NULL
,	NULL
pol	NULL
1	NULL
bypasses	NULL
UV	NULL
-	NULL
and	NULL
chemical-induced	NULL
lesions	NULL
by	NULL
inserting	NULL
deoxynucleotides	NULL
mostly	NULL
in	NULL
an	NULL
error-free	NULL
fashion	NULL
in	NULL
yeast	NULL
,	NULL
mouse	NULL
,	NULL
and	NULL
human	NULL
cells	NULL
,	NULL
as	NULL
it	NULL
favors	NULL
the	NULL
intervention	NULL
of	NULL
exogenous	NULL
3	NULL
``	NULL
-	NULL
5	NULL
``	NULL
exonucleases	NULL
(	NULL
Johnson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
19992	NULL
,	NULL
1999	NULL
,	NULL
2000c	NULL
;	NULL
Washington	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
;	NULL
Masutani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999a	NULL
;	NULL
Haracska	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
;	NULL
Yamada	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

As	NULL
we	NULL
(	NULL
Diaz	NULL
and	NULL
Flajnik	NULL
,	NULL
1998	NULL
;	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000b	NULL
)	NULL
and	NULL
others	NULL
(	NULL
Papavasiliou	NULL
and	NULL
Schatz	NULL
,	NULL
2000	NULL
;	NULL
Poltoratsky	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
have	NULL
suggested	NULL
,	NULL
the	NULL
modalities	NULL
of	NULL
Ig	NULL
and	NULL
be/-6	NULL
somatic	NULL
mutations	NULL
seem	NULL
to	NULL
best	NULL
reflect	NULL
the	NULL
functional	NULL
features	NULL
of	NULL
pol	NULL
&	NULL
(	NULL
Papavasiliou	NULL
and	NULL
Schatz	NULL
,	NULL
2000	NULL
;	NULL
Poltoratsky	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

This	NULL
polymerase	NULL
effectively	NULL
extends	NULL
DNA	NULL
past	NULL
a	NULL
lesion	NULL
(	NULL
mispair	NULL
extender	NULL
)	NULL
with	NULL
relative	NULL
high	NULL
fidelity	NULL
,	NULL
possibly	NULL
after	NULL
the	NULL
insertion	NULL
of	NULL
one	NULL
or	NULL
two	NULL
mismatched	NULL
nucleotides	NULL
by	NULL
a	NULL
low	NULL
processivity	NULL
,	NULL
error-prone	NULL
polymerase	NULL
(	NULL
mispair	NULL
inserter	NULL
)	NULL
,	NULL
such	NULL
as	NULL
the	NULL
recently	NULL
identified	NULL
pol	NULL
1	NULL
(	NULL
Rad30B	NULL
)	NULL
(	NULL
Tissier	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
,	NULL
pol	NULL
x	NULL
(	NULL
Ohashi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
,	NULL
pol	NULL
A	NULL
(	NULL
Aoufouchi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
;	NULL
Garcia-Diaz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
,	NULL
or	NULL
,	NULL
perhaps	NULL
,	NULL
pol	NULL
u	NULL
(	NULL
Aoufouchi	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Results	NULL
Page	NULL
3	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
;	NULL
Dominguez	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

Disruption	NULL
of	NULL
the	NULL
pol	NULL
{	NULL
REV3	NULL
gene	NULL
in	NULL
mice	NULL
results	NULL
in	NULL
early	NULL
embryonic	NULL
lethality	NULL
(	NULL
Bemark	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
;	NULL
Esposito	NULL
et	NULL
al	NULL
.	NULL

,	NULL
20002	NULL
)	NULL
.	NULL

However	NULL
,	NULL
human	NULL
fibroblasts	NULL
in	NULL
which	NULL
REV3	NULL
gene	NULL
expression	NULL
is	NULL
inhibited	NULL
by	NULL
an	NULL
antisense	NULL
REV3	NULL
fragment	NULL
display	NULL
impaired	NULL
damage-induced	NULL
mutagenesis	NULL
but	NULL
normal	NULL
growth	NULL
(	NULL
Gibbs	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
addressed	NULL
the	NULL
role	NULL
of	NULL
pol	NULL
&	NULL
in	NULL
hypermutation	NULL
using	NULL
human	NULL
B	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
show	NULL
that	NULL
pol	NULL
&	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
hypermutation	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
the	NULL
significant	NULL
reduction	NULL
of	NULL
somatic	NULL
Ig	NULL
and	NULL
be/-6	NULL
hypermutation	NULL
in	NULL
B	NULL
cells	NULL
in	NULL
which	NULL
pol	NULL
&	NULL
mRNA	NULL
transcripts	NULL
were	NULL
inhibited	NULL
by	NULL
specific	NULL
oligonucleotides	NULL
.	NULL

We	NULL
also	NULL
show	NULL
that	NULL
pol	NULL
&	NULL
is	NULL
upregulated	NULL
by	NULL
B	NULL
cell	NULL
receptor	NULL
(	NULL
BCR	NULL
)	NULL
engagement	NULL
,	NULL
which	NULL
simultaneously	NULL
downregulates	NULL
pol	NULL
1	NULL
,	NULL
thereby	NULL
making	NULL
pol	NULL
£	NULL
mispair	NULL
extender	NULL
activity	NULL
abundantly	NULL
available	NULL
to	NULL
possibly	NULL
mutate	NULL
Ig	NULL
and	NULL
bei-6	NULL
DNA	NULL
.	NULL

Pol	NULL
€	NULL
Is	NULL
Upregulated	NULL
and	NULL
pol	NULL
n	NULL
Is	NULL
Downregulated	NULL
in	NULL
Mutating	NULL
Human	NULL
B	NULL
Cells	NULL
Ig	NULL
V	NULL
(	NULL
D	NULL
)	NULL
J	NULL
and	NULL
be/-6	NULL
hypermutation	NULL
occurs	NULL
in	NULL
germinal	NULL
centers	NULL
of	NULL
secondary	NULL
lymphoid	NULL
organs	NULL
,	NULL
such	NULL
as	NULL
tonsils	NULL
and	NULL
lymph	NULL
nodes	NULL
,	NULL
during	NULL
the	NULL
transition	NULL
from	NULL
IgD*CD38~	NULL
naive	NULL
B	NULL
cell	NULL
to	NULL
IgD*CD38*	NULL
early	NULL
centroblast	NULL
and	NULL
IgD-CD38*	NULL
full-blown	NULL
centroblast	NULL
,	NULL
with	NULL
some	NULL
IgD*CD38*	NULL
B	NULL
cells	NULL
displaying	NULL
an	NULL
uncommonly	NULL
high	NULL
frequency	NULL
of	NULL
somatic	NULL
mutations	NULL
,	NULL
possibly	NULL
as	NULL
a	NULL
result	NULL
of	NULL
the	NULL
sequestration	NULL
of	NULL
this	NULL
subpopulation	NULL
in	NULL
the	NULL
germinal	NULL
center	NULL
environment	NULL
(	NULL
Pascual	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Wilson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

In	NULL
human	NULL
tonsils	NULL
,	NULL
highly	NULL
mutated	NULL
V	NULL
(	NULL
D	NULL
)	NULL
J	NULL
and	NULL
be/-6	NULL
DNA	NULL
sequences	NULL
are	NULL
found	NULL
in	NULL
CD38*	NULL
germinal	NULL
center	NULL
and	NULL
CD38~	NULL
memory	NULL
but	NULL
not	NULL
in	NULL
CD38~	NULL
naive	NULL
B	NULL
cells	NULL
(	NULL
Pascual	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Pasqualucci	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Shen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Wilson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

To	NULL
analyze	NULL
the	NULL
involvement	NULL
of	NULL
DNA	NULL
polymerases	NULL
in	NULL
somatic	NULL
hypermutation	NULL
,	NULL
we	NULL
sorted	NULL
tonsillar	NULL
B	NULL
lymphocytes	NULL
into	NULL
IgD*CD38~	NULL
(	NULL
naive	NULL
B	NULL
cells	NULL
)	NULL
,	NULL
IgD*CD38*	NULL
(	NULL
early	NULL
centroblasts	NULL
)	NULL
,	NULL
IgD-~CD38*	NULL
(	NULL
germinal	NULL
center	NULL
centroblasts	NULL
and	NULL
cen	NULL
trocytes	NULL
)	NULL
,	NULL
and	NULL
IgD	NULL
-	NULL
CD38~	NULL
(	NULL
memory	NULL
B	NULL
cells	NULL
)	NULL
fractions	NULL
and	NULL
measured	NULL
the	NULL
expression	NULL
of	NULL
DNA	NULL
pol	NULL
£	NULL
REV3	NULL
and	NULL
pol	NULL
n	NULL
(	NULL
RAD3OA	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
pol	NULL
1	NULL
(	NULL
RAD3OB	NULL
)	NULL
,	NULL
pol	NULL
a	NULL
,	NULL
pol	NULL
B	NULL
,	NULL
pol	NULL
8	NULL
,	NULL
pol	NULL
&	NULL
,	NULL
pol	NULL
x	NULL
,	NULL
and	NULL
pol	NULL
u	NULL
by	NULL
RT-PCR	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

The	NULL
sizes	NULL
of	NULL
all	NULL
amplified	NULL
cDNAs	NULL
were	NULL
as	NULL
predicted	NULL
,	NULL
and	NULL
,	NULL
in	NULL
each	NULL
case	NULL
,	NULL
the	NULL
cDNA	NULL
was	NULL
cloned	NULL
and	NULL
found	NULL
to	NULL
contain	NULL
the	NULL
correct	NULL
coding	NULL
sequence	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Pol	NULL
a	NULL
,	NULL
pol	NULL
B	NULL
,	NULL
pol	NULL
8	NULL
,	NULL
pol	NULL
g	NULL
,	NULL
and	NULL
the	NULL
error-prone	NULL
pol	NULL
1	NULL
and	NULL
pol	NULL
x	NULL
were	NULL
expressed	NULL
at	NULL
comparable	NULL
levels	NULL
in	NULL
IgD*CD387	NULL
,	NULL
IgD*CD38*	NULL
,	NULL
IgD-CD38*	NULL
,	NULL
and	NULL
IgD-CD38~	NULL
B	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
gene	NULL
encoding	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
the	NULL
translesion	NULL
pol	NULL
{	NULL
REV3	NULL
was	NULL
expressed	NULL
at	NULL
significantly	NULL
higher	NULL
levels	NULL
in	NULL
the	NULL
mutating	NULL
IgD*CD38*	NULL
and	NULL
IgD-CD38*	NULL
B	NULL
cells	NULL
than	NULL
in	NULL
the	NULL
nonmutating	NULL
IgD*CD38~	NULL
and	NULL
IgD-CD38~	NULL
B	NULL
cells	NULL
(	NULL
Pascual	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Shen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Wilson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

The	NULL
error-prone	NULL
pol	NULL
u	NULL
was	NULL
equally	NULL
expressed	NULL
in	NULL
IgD*CD38~	NULL
,	NULL
IgD-~CD38*	NULL
,	NULL
and	NULL
IgD	NULL
CD38	NULL
,	NULL
B	NULL
cells	NULL
but	NULL
slightly	NULL
upregulated	NULL
in	NULL
IgD*CD38*	NULL
cells	NULL
.	NULL

Pol	NULL
1	NULL
,	NULL
which	NULL
can	NULL
perform	NULL
error-free	NULL
translesion	NULL
DNA	NULL
synthesis	NULL
,	NULL
was	NULL
expressed	NULL
in	NULL
IgD*CD38~	NULL
and	NULL
slightly	NULL
decreased	NULL
in	NULL
IgD	NULL
-	NULL
CD38~	NULL
B	NULL
cells	NULL
but	NULL
significantly	NULL
downregulated	NULL
in	NULL
IgD*CD38+*	NULL
and	NULL
IgD-~CD38*	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
VgDJy-C8	NULL
transcripts	NULL
in	NULL
IgD	NULL
-	NULL
CD38*	NULL
and	NULL
IgD	NULL
-	NULL
CD38~	NULL
lymphocytes	NULL
confirmed	NULL
the	NULL
(	NULL
centroblastic	NULL
and	NULL
centrocytic	NULL
)	NULL
germinal	NULL
center	NULL
and	NULL
memory	NULL
phenotype	NULL
,	NULL
respectively	NULL
,	NULL
of	NULL
these	NULL
B	NULL
cells	NULL
,	NULL
while	NULL
the	NULL
comparable	NULL
amounts	NULL
of	NULL
amplified	NULL
CD79b	NULL
and	NULL
B-actin	NULL
cDNA	NULL
indicated	NULL
that	NULL
comparable	NULL
numbers	NULL
of	NULL
cells	NULL
were	NULL
analyzed	NULL
for	NULL
each	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
4	NULL
fraction	NULL
.	NULL

The	NULL
differential	NULL
expression	NULL
of	NULL
DNA	NULL
pol	NULL
{	NULL
and	NULL
pol	NULL
1	NULL
in	NULL
the	NULL
tonsillar	NULL
B	NULL
cell	NULL
subsets	NULL
was	NULL
emphasized	NULL
by	NULL
the	NULL
amplification	NULL
of	NULL
these	NULL
polymerases	NULL
in	NULL
the	NULL
same	NULL
vessel	NULL
,	NULL
together	NULL
with	NULL
f-actin	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
,	NULL
and	NULL
was	NULL
confirmed	NULL
by	NULL
multiple	NULL
RT-PCRs	NULL
using	NULL
serially	NULL
diluted	NULL
cDNAs	NULL
(	NULL
see	NULL
Supplemental	NULL
Figure	NULL
S1	NULL
at	NULL
http	NULL
:	NULL
//www.immunity.com/cgi/content/full/14/5/645/DC1	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
ex	NULL
vivo	NULL
experiments	NULL
show	NULL
that	NULL
human	NULL
tonsillar	NULL
IgD*CD38*	NULL
and	NULL
IgD-CD38*	NULL
B	NULL
cells	NULL
,	NULL
which	NULL
undergo	NULL
intensive	NULL
Ig	NULL
hypermutation	NULL
in	NULL
response	NULL
to	NULL
antigen	NULL
binding	NULL
and	NULL
T	NULL
cell	NULL
help	NULL
,	NULL
display	NULL
a	NULL
significant	NULL
alteration	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
translesion	NULL
DNA	NULL
pol	NULL
&	NULL
and	NULL
pol	NULL
n.	NULL
BCR	NULL
Induces	NULL
Upregulation	NULL
of	NULL
pol	NULL
C	NULL
,	NULL
Downregulation	NULL
of	NULL
pol	NULL
n	NULL
,	NULL
and	NULL
Ig	NULL
VH	NULL
;	NULL
DJp	NULL
Hypermutation	NULL
As	NULL
we	NULL
have	NULL
shown	NULL
in	NULL
human	NULL
IgM	NULL
'IgD*	NULL
B	NULL
cells	NULL
,	NULL
contact	NULL
with	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
is	NULL
sufficient	NULL
to	NULL
induce	NULL
Ig	NULL
class	NULL
switching	NULL
and	NULL
germinal	NULL
center-like	NULL
differentiation	NULL
(	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998a	NULL
,	NULL
1998b	NULL
,	NULL
2000	NULL
;	NULL
Schaffer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
,	NULL
but	NULL
induction	NULL
of	NULL
somatic	NULL
hypermutation	NULL
requires	NULL
BCR	NULL
engagement	NULL
(	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
,	NULL
2000a	NULL
)	NULL
.	NULL

We	NULL
hypothesized	NULL
that	NULL
the	NULL
pol	NULL
£	NULL
and	NULL
pol	NULL
1	NULL
up-	NULL
and	NULL
downregulation	NULL
found	NULL
in	NULL
mutating	NULL
B	NULL
cells	NULL
was	NULL
induced	NULL
by	NULL
the	NULL
antigen-mediated	NULL
crosslinking	NULL
of	NULL
the	NULL
BCR	NULL
on	NULL
these	NULL
germinal	NULL
center	NULL
lymphocytes	NULL
.	NULL

We	NULL
used	NULL
our	NULL
human	NULL
monoclonal	NULL
CL-O1	NULL
B	NULL
cell	NULL
line	NULL
to	NULL
prove	NULL
that	NULL
BCR	NULL
engagement	NULL
modulates	NULL
pol	NULL
&	NULL
and	NULL
pol	NULL
n	NULL
levels	NULL
and	NULL
that	NULL
this	NULL
DNA	NULL
polymerase	NULL
modulation	NULL
is	NULL
associated	NULL
with	NULL
somatic	NULL
hypermutation	NULL
.	NULL

CL-01	NULL
B	NULL
cells	NULL
are	NULL
Ig	NULL
M	NULL
*'IgD*	NULL
and	NULL
,	NULL
upon	NULL
engagement	NULL
of	NULL
BCR	NULL
and	NULL
contact	NULL
with	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
undergo	NULL
Ig	NULL
class	NULL
switching	NULL
and	NULL
effectively	NULL
mutate	NULL
the	NULL
Ig	NULL
V	NULL
(	NULL
D	NULL
)	NULL
J	NULL
and	NULL
bei-6	NULL
genes	NULL
at	NULL
a	NULL
rate	NULL
and	NULL
with	NULL
modalities	NULL
that	NULL
mimic	NULL
those	NULL
of	NULL
B	NULL
cells	NULL
in	NULL
vivo	NULL
(	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
,	NULL
20002	NULL
)	NULL
.	NULL

In	NULL
these	NULL
B	NULL
cells	NULL
,	NULL
BCR	NULL
engagement	NULL
increased	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
pol	NULL
{	NULL
REV3	NULL
catalytic	NULL
subunit	NULL
while	NULL
virtually	NULL
ablating	NULL
pol	NULL
1	NULL
expression	NULL
and	NULL
,	NULL
together	NULL
with	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
induced	NULL
Ig	NULL
VyDJy	NULL
gene	NULL
hypermutation	NULL
(	NULL
28	NULL
nucleotide	NULL
changes	NULL
in	NULL
112.5	NULL
kb	NULL
analyzed	NULL
)	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

No	NULL
alteration	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
pol	NULL
&	NULL
and	NULL
pol	NULL
1	NULL
and	NULL
no	NULL
hypermutation	NULL
occurred	NULL
in	NULL
similar	NULL
B	NULL
cells	NULL
cultured	NULL
with	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
without	NULL
BCR	NULL
engagement	NULL
(	NULL
two	NULL
changes	NULL
in	NULL
94	NULL
kb	NULL
)	NULL
or	NULL
cultured	NULL
with	NULL
nil	NULL
,	NULL
with	NULL
(	NULL
two	NULL
changes	NULL
in	NULL
75	NULL
kb	NULL
)	NULL
or	NULL
without	NULL
(	NULL
one	NULL
change	NULL
in	NULL
56	NULL
kb	NULL
)	NULL
reaction	NULL
with	NULL
anti-BCR	NULL
Ab	NULL
.	NULL

Consistent	NULL
with	NULL
our	NULL
previous	NULL
findings	NULL
(	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
,	NULL
20002	NULL
,	NULL
2000b	NULL
)	NULL
,	NULL
the	NULL
B	NULL
cells	NULL
cultured	NULL
with	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
without	NULL
BCR	NULL
engagement	NULL
underwent	NULL
Ig	NULL
class	NULL
switching	NULL
and	NULL
germinal	NULL
center	NULL
phenotypic	NULL
differentiation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
the	NULL
reciprocal	NULL
modulation	NULL
of	NULL
DNA	NULL
pol	NULL
&	NULL
and	NULL
pol	NULL
n	NULL
was	NULL
further	NULL
emphasized	NULL
by	NULL
the	NULL
relatively	NULL
constant	NULL
levels	NULL
of	NULL
pol	NULL
1	NULL
,	NULL
pol	NULL
a	NULL
,	NULL
pol	NULL
B	NULL
,	NULL
pol	NULL
8	NULL
,	NULL
pol	NULL
g	NULL
,	NULL
and	NULL
pol	NULL
u	NULL
in	NULL
B	NULL
cells	NULL
reacted	NULL
or	NULL
not	NULL
reacted	NULL
with	NULL
anti-BCR	NULL
Ab	NULL
and	NULL
cultured	NULL
with	NULL
or	NULL
without	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
by	NULL
further	NULL
analysis	NULL
involving	NULL
multiple	NULL
RT-PCRs	NULL
using	NULL
serially	NULL
diluted	NULL
cDNAs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
in	NULL
vitro	NULL
experiments	NULL
show	NULL
that	NULL
BCR	NULL
engagement	NULL
effectively	NULL
modulates	NULL
pol	NULL
{	NULL
and	NULL
pol	NULL
1	NULL
,	NULL
expression	NULL
and	NULL
induces	NULL
Ig	NULL
hypermutation	NULL
in	NULL
a	NULL
fashion	NULL
that	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
findings	NULL
in	NULL
ex	NULL
vivo	NULL
tonsillar	NULL
B	NULL
cells	NULL
.	NULL

BCR-Induced	NULL
pol	NULL
C	NULL
and	NULL
pol	NULL
n	NULL
Regulation	NULL
Is	NULL
Dose	NULL
and	NULL
Time	NULL
Dependent	NULL
To	NULL
assess	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
BCR-induced	NULL
modulation	NULL
of	NULL
DNA	NULL
polymerase	NULL
expression	NULL
,	NULL
we	NULL
treated	NULL
human	NULL
CL-O01	NULL
IgM	NULL
*IgD*	NULL
B	NULL
cells	NULL
with	NULL
increasing	NULL
amounts	NULL
of	NULL
anti-BCR	NULL
Ab	NULL
and	NULL
measured	NULL
by	NULL
RT-PCR	NULL
the	NULL
levels	NULL
of	NULL
pol	NULL
&	NULL
,	NULL
pol	NULL
1	NULL
,	NULL
pol	NULL
i	NULL
,	NULL
pol	NULL
a	NULL
,	NULL
pol	NULL
8	NULL
,	NULL
pol	NULL
s	NULL
,	NULL
pol	NULL
k	NULL
,	NULL
and	NULL
pol	NULL
u	NULL
in	NULL
these	NULL
cells	NULL
after	NULL
12	NULL
hr	NULL
of	NULL
culture	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
results	NULL
of	NULL
the	NULL
ex	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
experiments	NULL
(	NULL
Figures	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
these	NULL
DNA	NULL
polymerases	NULL
were	NULL
all	NULL
constitutively	NULL
expressed	NULL
in	NULL
the	NULL
B	NULL
cells	NULL
(	NULL
Figures	NULL
3A	NULL
and	NULL
3B	NULL
)	NULL
.	NULL

Pol	NULL
{	NULL
REV3	NULL
was	NULL
upregulated	NULL
in	NULL
a	NULL
dose	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
5	NULL
dependent	NULL
fashion	NULL
by	NULL
BCR	NULL
engagement	NULL
,	NULL
which	NULL
induced	NULL
a	NULL
concomitant	NULL
downregulation	NULL
of	NULL
pol	NULL
1	NULL
but	NULL
no	NULL
significant	NULL
changes	NULL
in	NULL
pol	NULL
1	NULL
,	NULL
pol	NULL
a	NULL
,	NULL
pol	NULL
8	NULL
,	NULL
pol	NULL
s	NULL
,	NULL
pol	NULL
x	NULL
,	NULL
and	NULL
pol	NULL
u	NULL
.	NULL

The	NULL
reciprocal	NULL
modulation	NULL
of	NULL
pol	NULL
&	NULL
and	NULL
pol	NULL
1	NULL
,	NULL
began	NULL
as	NULL
early	NULL
as	NULL
1	NULL
hr	NULL
after	NULL
BCR	NULL
engagement	NULL
,	NULL
peaked	NULL
within	NULL
9-24	NULL
hr	NULL
,	NULL
and	NULL
lasted	NULL
as	NULL
long	NULL
as	NULL
48	NULL
hr	NULL
after	NULL
a	NULL
single	NULL
treatment	NULL
of	NULL
B	NULL
cells	NULL
with	NULL
anti-BCR	NULL
Ab	NULL
(	NULL
Figure	NULL
3C	NULL
)	NULL
.	NULL

It	NULL
was	NULL
reproduced	NULL
in	NULL
freshly	NULL
isolated	NULL
normal	NULL
human	NULL
IgM	NULL
IgD*	NULL
B	NULL
cells	NULL
(	NULL
Figure	NULL
3D	NULL
)	NULL
and	NULL
confirmed	NULL
by	NULL
multiple	NULL
RT-PCRs	NULL
using	NULL
serially	NULL
diluted	NULL
cDNAs	NULL
(	NULL
Supplemental	NULL
Figure	NULL
S1	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

It	NULL
was	NULL
not	NULL
due	NULL
to	NULL
lymphocyte	NULL
proliferation	NULL
or	NULL
differentiation	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
the	NULL
demonstration	NULL
that	NULL
CD154	NULL
or	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
which	NULL
provide	NULL
strong	NULL
B	NULL
cell	NULL
proliferation	NULL
and	NULL
differentiation	NULL
stimuli	NULL
,	NULL
did	NULL
not	NULL
influence	NULL
the	NULL
expression	NULL
of	NULL
pol	NULL
E	NULL
,	NULL
pol	NULL
1	NULL
,	NULL
pol	NULL
i	NULL
,	NULL
pol	NULL
a	NULL
,	NULL
pol	NULL
8	NULL
,	NULL
pol	NULL
s	NULL
,	NULL
pol	NULL
x	NULL
,	NULL
or	NULL
pol	NULL
u	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
BCR	NULL
engagement	NULL
(	NULL
Figure	NULL
2	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
lack	NULL
of	NULL
hypermutation	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
Bachl	NULL
and	NULL
Wabl	NULL
,	NULL
1995	NULL
)	NULL
,	NULL
TCR	NULL
complex	NULL
crosslinking	NULL
by	NULL
an	NULL
anti-CD3	NULL
Ab	NULL
did	NULL
not	NULL
modulate	NULL
the	NULL
expression	NULL
of	NULL
pol	NULL
{	NULL
or	NULL
pol	NULL
1	NULL
in	NULL
freshly	NULL
isolated	NULL
normal	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
Figure	NULL
3E	NULL
)	NULL
.	NULL

Specific	NULL
Inhibition	NULL
of	NULL
pol	NULL
€	NULL
Impairs	NULL
Ig	NULL
and	NULL
be/-6	NULL
Somatic	NULL
Hypermutation	NULL
and	NULL
Damage-Induced	NULL
DNA	NULL
Mutagenesis	NULL
in	NULL
Human	NULL
B	NULL
Cells	NULL
We	NULL
used	NULL
specific	NULL
phosphorothioate	NULL
oligonucleotides	NULL
to	NULL
inhibit	NULL
the	NULL
pol	NULL
&	NULL
REV3	NULL
catalytic	NULL
subunit	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
induced	NULL
by	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
upon	NULL
BCR	NULL
engagement	NULL
.	NULL

The	NULL
oligonucleotides	NULL
were	NULL
introduced	NULL
into	NULL
CL-O1	NULL
cells	NULL
,	NULL
using	NULL
the	NULL
cationic	NULL
lipid	NULL
Cytofectin	NULL
GSV	NULL
(	NULL
Lewis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
which	NULL
in	NULL
our	NULL
hands	NULL
has	NULL
yielded	NULL
consistently	NULL
more	NULL
than	NULL
85	NULL
%	NULL
transfection	NULL
efficiency	NULL
,	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
2	NULL
uM	NULL
,	NULL
starting	NULL
at	NULL
day	NULL
-1	NULL
(	NULL
a	NULL
day	NULL
prior	NULL
to	NULL
stimulation	NULL
with	NULL
anti-BCR	NULL
Ab	NULL
and	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
)	NULL
and	NULL
every	NULL
day	NULL
thereafter	NULL
.	NULL

Pol	NULL
{	NULL
REV3	NULL
catalytic	NULL
subunit	NULL
,	NULL
pol	NULL
1	NULL
,	NULL
pol	NULL
i	NULL
,	NULL
pol	NULL
a	NULL
,	NULL
pol	NULL
B	NULL
,	NULL
and	NULL
pol	NULL
u	NULL
transcripts	NULL
were	NULL
determined	NULL
by	NULL
specific	NULL
RT-PCR	NULL
at	NULL
days	NULL
1	NULL
,	NULL
2	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
9	NULL
,	NULL
and	NULL
14	NULL
of	NULL
culture	NULL
;	NULL
mutated	NULL
Ig	NULL
VgDJy	NULL
and	NULL
be/-6	NULL
transcripts	NULL
were	NULL
analyzed	NULL
after	NULL
14	NULL
days	NULL
of	NULL
culture	NULL
,	NULL
as	NULL
in	NULL
the	NULL
experiments	NULL
of	NULL
Figure	NULL
2	NULL
.	NULL

REV3	NULL
transcripts	NULL
were	NULL
significantly	NULL
reduced	NULL
by	NULL
the	NULL
specific	NULL
sense	NULL
SQ1	NULL
and	NULL
antisense	NULL
ASO1	NULL
but	NULL
not	NULL
the	NULL
scrambled	NULL
(	NULL
SCRA	NULL
)	NULL
or	NULL
the	NULL
antisense	NULL
ASQ2	NULL
and	NULL
ASO3	NULL
oligonucleotides	NULL
,	NULL
as	NULL
early	NULL
as	NULL
36	NULL
hr	NULL
after	NULL
the	NULL
initiation	NULL
of	NULL
the	NULL
culture	NULL
,	NULL
and	NULL
remained	NULL
such	NULL
throughout	NULL
day	NULL
14	NULL
(	NULL
Figure	NULL
4A	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

None	NULL
of	NULL
the	NULL
oligonucleotides	NULL
inhibited	NULL
pol	NULL
1	NULL
,	NULL
pol	NULL
a	NULL
,	NULL
pol	NULL
B	NULL
,	NULL
or	NULL
pol	NULL
u	NULL
expression	NULL
.	NULL

The	NULL
pol	NULL
{	NULL
inhibition	NULL
was	NULL
confirmed	NULL
by	NULL
multiple	NULL
RT-PCRs	NULL
,	NULL
using	NULL
different	NULL
numbers	NULL
of	NULL
cycles	NULL
and	NULL
serially	NULL
diluted	NULL
cDNAs	NULL
(	NULL
Supplemental	NULL
Figure	NULL
S1	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

An	NULL
overall	NULL
comparable	NULL
pattern	NULL
of	NULL
DNA	NULL
polymerase	NULL
modulations	NULL
was	NULL
observed	NULL
in	NULL
B	NULL
cells	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
and	NULL
without	NULL
BCR	NULL
engagement	NULL
(	NULL
Figure	NULL
4B	NULL
)	NULL
.	NULL

The	NULL
reduced	NULL
pol	NULL
£	NULL
expression	NULL
resulted	NULL
in	NULL
impaired	NULL
Ig	NULL
VgDJy	NULL
and	NULL
be/-6	NULL
hypermutation	NULL
.	NULL

As	NULL
we	NULL
have	NULL
shown	NULL
(	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000a	NULL
)	NULL
,	NULL
be/-6	NULL
mutates	NULL
in	NULL
response	NULL
to	NULL
the	NULL
same	NULL
stimuli	NULL
and	NULL
with	NULL
the	NULL
same	NULL
modalities	NULL
as	NULL
Ig	NULL
V	NULL
(	NULL
D	NULL
)	NULL
J	NULL
genes	NULL
.	NULL

As	NULL
determined	NULL
by	NULL
single-strand	NULL
DNA	NULL
conformation	NULL
polymorphism	NULL
(	NULL
SSCP	NULL
)	NULL
analysis	NULL
,	NULL
CL-O1	NULL
cells	NULL
cocultured	NULL
,	NULL
upon	NULL
BCR	NULL
engagement	NULL
,	NULL
with	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
for	NULL
14	NULL
days	NULL
with	NULL
daily	NULL
treatment	NULL
of	NULL
the	NULL
scrambled	NULL
(	NULL
SCRA	NULL
)	NULL
oligonucleotide	NULL
,	NULL
and	NULL
Cytofectin	NULL
GSV	NULL
mutated	NULL
as	NULL
many	NULL
as	NULL
12.31	NULL
%	NULL
and	NULL
9.62	NULL
%	NULL
of	NULL
the	NULL
375	NULL
bp	NULL
Ig	NULL
VygDJy	NULL
,	NULL
and	NULL
the	NULL
226	NULL
bp	NULL
bei-6	NULL
Exon	NULL
I	NULL
cDNA	NULL
segments	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
yielding	NULL
a	NULL
frequency	NULL
of	NULL
mutations	NULL
of	NULL
3.28	NULL
x	NULL
10~*	NULL
and	NULL
4.25	NULL
x	NULL
10~*	NULL
change/base	NULL
,	NULL
respectively	NULL
(	NULL
Figure	NULL
4C	NULL
)	NULL
.	NULL

This	NULL
frequency	NULL
was	NULL
comparable	NULL
to	NULL
that	NULL
of	NULL
similarly	NULL
induced	NULL
CL-O1	NULL
cells	NULL
treated	NULL
with	NULL
Cytofectin	NULL
GSV	NULL
alone	NULL
(	NULL
nil	NULL
)	NULL
,	NULL
AS02	NULL
,	NULL
or	NULL
ASQ3	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
CL-01	NULL
cells	NULL
stimulated	NULL
with	NULL
anti-BCR	NULL
Ab	NULL
and	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
but	NULL
treated	NULL
daily	NULL
with	NULL
the	NULL
pol	NULL
£	NULL
REV3-specific	NULL
S01	NULL
or	NULL
AS01	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
6	NULL
oligonucleotide	NULL
and	NULL
Cytofectin	NULL
GSV	NULL
mutated	NULL
as	NULL
few	NULL
as	NULL
3.34	NULL
%	NULL
and	NULL
3.14	NULL
%	NULL
of	NULL
the	NULL
expressed	NULL
Ig	NULL
VgDJy	NULL
and	NULL
be/-6	NULL
transcripts	NULL
,	NULL
respectively	NULL
,	NULL
which	NULL
corresponded	NULL
to	NULL
about	NULL
73	NULL
%	NULL
reduction	NULL
(	NULL
p	NULL
<	NULL
0.001	NULL
)	NULL
in	NULL
mutation	NULL
frequency	NULL
,	NULL
as	NULL
compared	NULL
to	NULL
CL-O1	NULL
cells	NULL
treated	NULL
with	NULL
SCRA	NULL
,	NULL
ASO2	NULL
,	NULL
or	NULL
ASO3	NULL
or	NULL
Cytofectin	NULL
GSV	NULL
alone	NULL
.	NULL

This	NULL
decrease	NULL
in	NULL
Ig	NULL
and	NULL
be/-6	NULL
mutation	NULL
frequency	NULL
was	NULL
not	NULL
due	NULL
to	NULL
changes	NULL
in	NULL
cell	NULL
cycle	NULL
,	NULL
viability	NULL
,	NULL
or	NULL
proliferation	NULL
,	NULL
as	NULL
these	NULL
parameters	NULL
were	NULL
not	NULL
significantly	NULL
affected	NULL
by	NULL
Cytofectin	NULL
GSV	NULL
alone	NULL
and/or	NULL
the	NULL
different	NULL
phosphorothioate-modified	NULL
oligonucleotides	NULL
throughout	NULL
the	NULL
culture	NULL
period	NULL
(	NULL
Figures	NULL
5A	NULL
and	NULL
5B	NULL
)	NULL
but	NULL
was	NULL
associated	NULL
with	NULL
an	NULL
impairment	NULL
of	NULL
the	NULL
B	NULL
cells	NULL
to	NULL
copy	NULL
the	NULL
UV	NULL
-damaged	NULL
shuttle	NULL
pSP189	NULL
vector	NULL
DNA	NULL
(	NULL
Figure	NULL
4D	NULL
)	NULL
,	NULL
a	NULL
mutagenic	NULL
function	NULL
that	NULL
reflects	NULL
pol	NULL
&	NULL
Rev3	NULL
activity	NULL
(	NULL
Morrison	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Lawrence	NULL
and	NULL
Hinkle	NULL
,	NULL
1996	NULL
;	NULL
Nelson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Holbeck	NULL
and	NULL
Strathern	NULL
,	NULL
1997	NULL
;	NULL
Gibbs	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
,	NULL
2000	NULL
;	NULL
Lin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
;	NULL
Murakumo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
,	NULL
and	NULL
increased	NULL
cell	NULL
death	NULL
by	NULL
UV	NULL
light	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
Residual	NULL
Ig	NULL
VyDJp	NULL
and	NULL
be/-6	NULL
Mutations	NULL
Found	NULL
after	NULL
Inhibition	NULL
of	NULL
pol	NULL
C	NULL
Do	NULL
Not	NULL
Differ	NULL
from	NULL
Those	NULL
Introduced	NULL
in	NULL
the	NULL
Presence	NULL
of	NULL
pol	NULL
C	NULL
The	NULL
residual	NULL
Ig	NULL
VyDJy	NULL
and	NULL
be/-6	NULL
mutations	NULL
in	NULL
the	NULL
CL-01	NULL
cells	NULL
induced	NULL
by	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
upon	NULL
BCR-engagement	NULL
and	NULL
treated	NULL
with	NULL
the	NULL
REV3-specific	NULL
oligonucleotides	NULL
displayed	NULL
features	NULL
similar	NULL
to	NULL
those	NULL
found	NULL
in	NULL
the	NULL
CL-O01	NULL
cells	NULL
similarly	NULL
induced	NULL
but	NULL
treated	NULL
with	NULL
the	NULL
SCRA	NULL
oligonucleotide	NULL
or	NULL
Cytofectin	NULL
GSV	NULL
alone	NULL
.	NULL

The	NULL
56	NULL
Ig	NULL
and	NULL
23	NULL
be/-6	NULL
exon	NULL
1	NULL
mutated	NULL
cDNA	NULL
clones	NULL
from	NULL
the	NULL
induced	NULL
CL-O1	NULL
cells	NULL
treated	NULL
with	NULL
the	NULL
SCRA	NULL
oligonucleotide	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
bore	NULL
58	NULL
and	NULL
27	NULL
independent	NULL
point	NULL
mutations	NULL
,	NULL
respectively	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Of	NULL
the	NULL
total	NULL
85	NULL
point	NULL
mutations	NULL
,	NULL
55	NULL
(	NULL
65	NULL
%	NULL
)	NULL
were	NULL
transitions	NULL
,	NULL
while	NULL
randomly	NULL
occurring	NULL
point	NULL
mutations	NULL
would	NULL
be	NULL
expected	NULL
to	NULL
be	NULL
one-third	NULL
transitions	NULL
and	NULL
two-thirds	NULL
transversions	NULL
.	NULL

G	NULL
nucleotides	NULL
were	NULL
mutated	NULL
(	NULL
49.4	NULL
%	NULL
of	NULL
the	NULL
total	NULL
point	NULL
mutations	NULL
)	NULL
at	NULL
a	NULL
frequency	NULL
68	NULL
%	NULL
higher	NULL
than	NULL
expected	NULL
by	NULL
chance	NULL
alone	NULL
(	NULL
29.4	NULL
%	NULL
)	NULL
,	NULL
after	NULL
correcting	NULL
for	NULL
base	NULL
composition	NULL
,	NULL
with	NULL
G	NULL
-	NULL
>	NULL
A	NULL
transitions	NULL
accounting	NULL
for	NULL
69.0	NULL
%	NULL
of	NULL
the	NULL
total	NULL
G	NULL
mutations	NULL
and	NULL
52.7	NULL
%	NULL
of	NULL
all	NULL
transitions	NULL
.	NULL

The	NULL
residual	NULL
26	NULL
Ig	NULL
VygDJy	NULL
and	NULL
16	NULL
be/-6	NULL
exon	NULL
1	NULL
mutated	NULL
cDNA	NULL
clones	NULL
from	NULL
the	NULL
induced	NULL
CL-O01	NULL
cells	NULL
treated	NULL
with	NULL
the	NULL
REV3-specific	NULL
S01	NULL
and	NULL
ASO1	NULL
oligonucleotides	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
bore	NULL
26	NULL
and	NULL
17	NULL
independent	NULL
point	NULL
mutations	NULL
,	NULL
respectively	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Of	NULL
the	NULL
total	NULL
43	NULL
point	NULL
mutations	NULL
,	NULL
29	NULL
(	NULL
67.2	NULL
%	NULL
)	NULL
were	NULL
transitions	NULL
.	NULL

G	NULL
nucleotides	NULL
were	NULL
mutated	NULL
at	NULL
a	NULL
frequency	NULL
(	NULL
51.2	NULL
%	NULL
of	NULL
the	NULL
total	NULL
point	NULL
mutations	NULL
)	NULL
74.2	NULL
%	NULL
higher	NULL
than	NULL
that	NULL
expected	NULL
by	NULL
chance	NULL
alone	NULL
(	NULL
29.4	NULL
%	NULL
)	NULL
,	NULL
after	NULL
correcting	NULL
for	NULL
base	NULL
composition	NULL
,	NULL
with	NULL
G	NULL
-	NULL
>	NULL
A	NULL
transitions	NULL
accounting	NULL
and	NULL
58.6	NULL
%	NULL
for	NULL
77.3	NULL
%	NULL
of	NULL
the	NULL
total	NULL
G	NULL
mutations	NULL
of	NULL
all	NULL
transitions	NULL
.	NULL

Discussion	NULL
As	NULL
we	NULL
showed	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
Ig	NULL
and	NULL
be/-6	NULL
hypermutation	NULL
(	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
,	NULL
2000a	NULL
)	NULL
but	NULL
not	NULL
that	NULL
of	NULL
class	NULL
switch	NULL
DNA	NULL
recombination	NULL
(	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998a	NULL
,	NULL
1998b	NULL
,	NULL
2000	NULL
;	NULL
Schaffer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
requires	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
CD4*	NULL
T	NULL
cell	NULL
help	NULL
,	NULL
BCR	NULL
engagement	NULL
,	NULL
thereby	NULL
indicating	NULL
that	NULL
the	NULL
function	NULL
of	NULL
the	NULL
BCR	NULL
goes	NULL
beyond	NULL
providing	NULL
the	NULL
structural	NULL
correlate	NULL
for	NULL
the	NULL
selection	NULL
of	NULL
higher	NULL
affinity	NULL
mutants	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
,	NULL
in	NULL
B	NULL
cells	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
translesion	NULL
pol	NULL
{	NULL
is	NULL
effectively	NULL
modulated	NULL
by	NULL
BCR	NULL
engagement	NULL
and	NULL
that	NULL
the	NULL
inhibition	NULL
of	NULL
this	NULL
polymerase	NULL
by	NULL
specific	NULL
oligonucleotides	NULL
impairs	NULL
Ig	NULL
VyDJy	NULL
and	NULL
be/-6	NULL
hypermutation	NULL
and	NULL
,	NULL
to	NULL
a	NULL
comparable	NULL
extent	NULL
,	NULL
DNA	NULL
damage-induced	NULL
mutagenesis	NULL
without	NULL
affecting	NULL
cell	NULL
cycle	NULL
or	NULL
growth	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
,	NULL
pol	NULL
&	NULL
is	NULL
regulated	NULL
by	NULL
the	NULL
BCR	NULL
and	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
7	NULL
somatic	NULL
hypermutation	NULL
,	NULL
perhaps	NULL
facilitated	NULL
by	NULL
pol	NULL
n	NULL
downregulation	NULL
,	NULL
which	NULL
is	NULL
also	NULL
BCR	NULL
dependent	NULL
.	NULL

The	NULL
modulation	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
these	NULL
polymerases	NULL
may	NULL
be	NULL
regulated	NULL
not	NULL
only	NULL
at	NULL
the	NULL
transcriptional	NULL
but	NULL
also	NULL
the	NULL
posttranscriptional	NULL
level	NULL
.	NULL

B	NULL
cells	NULL
initiate	NULL
somatic	NULL
hypermutation	NULL
upon	NULL
exposure	NULL
to	NULL
antigen	NULL
and	NULL
activated	NULL
CD4¢*	NULL
T	NULL
cells	NULL
in	NULL
germinal	NULL
centers	NULL
of	NULL
secondary	NULL
lymphoid	NULL
organs	NULL
.	NULL

The	NULL
demonstration	NULL
that	NULL
BCR	NULL
engagement	NULL
signals	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
the	NULL
upregulation	NULL
of	NULL
pol	NULL
£	NULL
with	NULL
concomitant	NULL
downregula	NULL
tion	NULL
of	NULL
pol	NULL
n	NULL
,	NULL
while	NULL
inducing	NULL
Ig	NULL
and	NULL
be/-6	NULL
hypermutation	NULL
,	NULL
is	NULL
highly	NULL
consistent	NULL
with	NULL
the	NULL
findings	NULL
in	NULL
tonsillar	NULL
B	NULL
cells	NULL
:	NULL
pol	NULL
£	NULL
was	NULL
upregulated	NULL
and	NULL
pol	NULL
n	NULL
downregulated	NULL
in	NULL
IgD*CD38+*	NULL
and	NULL
IgD~CD38+*	NULL
B	NULL
cells	NULL
,	NULL
which	NULL
include	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
highly	NULL
hypermutating	NULL
B	NULL
lymphocytes	NULL
(	NULL
Pascual	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Wilson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
,	NULL
but	NULL
not	NULL
in	NULL
IgD*CD38~	NULL
naive	NULL
B	NULL
cells	NULL
,	NULL
which	NULL
express	NULL
unmutated	NULL
Ig	NULL
V	NULL
(	NULL
D	NULL
)	NULL
J	NULL
and	NULL
be/-6	NULL
genes	NULL
,	NULL
and	NULL
in	NULL
IgD	NULL
CD38~	NULL
memory	NULL
B	NULL
cells	NULL
,	NULL
which	NULL
express	NULL
mutated	NULL
Ig	NULL
V	NULL
(	NULL
D	NULL
)	NULL
J	NULL
and	NULL
be/-6	NULL
genes	NULL
,	NULL
but	NULL
in	NULL
which	NULL
the	NULL
hypermutation	NULL
process	NULL
is	NULL
extinct	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

The	NULL
demonstration	NULL
that	NULL
BCR	NULL
engagement	NULL
increases	NULL
pol	NULL
&	NULL
and	NULL
decreases	NULL
pol	NULL
1	NULL
but	NULL
does	NULL
not	NULL
lead	NULL
to	NULL
somatic	NULL
hypermutation	NULL
unless	NULL
activated	NULL
T	NULL
cells	NULL
are	NULL
also	NULL
present	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
suggests	NULL
that	NULL
accessibility	NULL
of	NULL
the	NULL
hypermutation	NULL
machinery	NULL
to	NULL
the	NULL
Ig	NULL
and	NULL
be/-6	NULL
loci	NULL
is	NULL
important	NULL
and	NULL
likely	NULL
requires	NULL
multiple	NULL
signals	NULL
.	NULL

Our	NULL
experiments	NULL
show	NULL
that	NULL
pol	NULL
&	NULL
,	NULL
which	NULL
is	NULL
essential	NULL
for	NULL
DNA	NULL
damage-induced	NULL
mutagenesis	NULL
(	NULL
Morrison	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Lawrence	NULL
and	NULL
Hinkle	NULL
,	NULL
1996	NULL
;	NULL
Nelson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Holbeck	NULL
and	NULL
Strathern	NULL
,	NULL
1997	NULL
;	NULL
Gibbs	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
,	NULL
2000	NULL
;	NULL
Lin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
;	NULL
Murakumo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
,	NULL
is	NULL
also	NULL
critical	NULL
for	NULL
the	NULL
hypermutation	NULL
of	NULL
both	NULL
the	NULL
Ig	NULL
and	NULL
be/-6	NULL
loci	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

In	NULL
spite	NULL
of	NULL
the	NULL
lack	NULL
of	NULL
3	NULL
'	NULL
-	NULL
>	NULL
5	NULL
``	NULL
exonuclease	NULL
activity	NULL
,	NULL
pol	NULL
{	NULL
copies	NULL
with	NULL
high	NULL
fidelity	NULL
undamaged	NULL
DNA	NULL
template	NULL
(	NULL
Johnson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000b	NULL
)	NULL
.	NULL

It	NULL
is	NULL
very	NULL
inefficient	NULL
in	NULL
inserting	NULL
deoxynucleotides	NULL
opposite	NULL
DNA	NULL
lesions	NULL
but	NULL
readily	NULL
extends	NULL
from	NULL
such	NULL
nucleotides	NULL
once	NULL
they	NULL
have	NULL
been	NULL
inserted	NULL
.	NULL

Indeed	NULL
,	NULL
it	NULL
extends	NULL
damaged	NULL
DNA	NULL
efficiently	NULL
,	NULL
in	NULL
concert	NULL
with	NULL
the	NULL
error-prone	NULL
,	NULL
low	NULL
processivity	NULL
pol	NULL
i	NULL
,	NULL
after	NULL
the	NULL
incorporation	NULL
of	NULL
one	NULL
or	NULL
two	NULL
mismatched	NULL
deoxynucleotides	NULL
opposite	NULL
DNA	NULL
lesions	NULL
by	NULL
this	NULL
polymerase	NULL
(	NULL
Johnson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000b	NULL
)	NULL
.	NULL

Pol	NULL
1	NULL
and	NULL
pol	NULL
&	NULL
act	NULL
sequentially	NULL
:	NULL
pol	NULL
1	NULL
as	NULL
a	NULL
``	NULL
mispair	NULL
inserter	NULL
``	NULL
and	NULL
pol	NULL
&	NULL
as	NULL
``	NULL
mispair	NULL
extender	NULL
.	NULL
``	NULL

The	NULL
central	NULL
role	NULL
of	NULL
pol	NULL
{	NULL
in	NULL
damage-induced	NULL
mutagenesis	NULL
would	NULL
be	NULL
reflected	NULL
in	NULL
the	NULL
central	NULL
role	NULL
of	NULL
this	NULL
polymerase	NULL
in	NULL
hypermutation	NULL
.	NULL

In	NULL
Saccharomyces	NULL
cerevisiae	NULL
,	NULL
pol	NULL
C	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
most	NULL
mutations	NULL
associated	NULL
with	NULL
transcription	NULL
(	NULL
Datta	NULL
and	NULL
Jinks-Robertson	NULL
,	NULL
1995	NULL
)	NULL
and	NULL
,	NULL
by	NULL
engaging	NULL
sites	NULL
near	NULL
DNA	NULL
breaks	NULL
,	NULL
to	NULL
increase	NULL
the	NULL
frequency	NULL
of	NULL
base	NULL
substitutions	NULL
in	NULL
the	NULL
vicinity	NULL
of	NULL
breaks	NULL
by	NULL
at	NULL
least	NULL
100-fold	NULL
(	NULL
Strathern	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Holbeck	NULL
and	NULL
Strathern	NULL
,	NULL
1997	NULL
)	NULL
.	NULL

Both	NULL
transcription	NULL
and	NULL
DNA	NULL
breaks	NULL
would	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
B	NULL
cell	NULL
somatic	NULL
hypermutation	NULL
process	NULL
.	NULL

The	NULL
meaning	NULL
of	NULL
the	NULL
BCR-induced	NULL
downregulation	NULL
of	NULL
pol	NULL
1	NULL
in	NULL
human	NULL
hypermutating	NULL
B	NULL
cells	NULL
in	NULL
vivo	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
and	NULL
in	NULL
vitro	NULL
(	NULL
Figures	NULL
2	NULL
and	NULL
4	NULL
)	NULL
is	NULL
unclear	NULL
.	NULL

Pol	NULL
n	NULL
lacks	NULL
proofreading	NULL
3	NULL
``	NULL
-	NULL
5	NULL
``	NULL
exonuclease	NULL
activity	NULL
,	NULL
but	NULL
its	NULL
low	NULL
processivity	NULL
allows	NULL
for	NULL
extrinsic	NULL
exonucleases	NULL
to	NULL
proofread	NULL
the	NULL
mismatched	NULL
nucleotides	NULL
it	NULL
inserts	NULL
(	NULL
Bebenek	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2001	NULL
)	NULL
.	NULL

This	NULL
,	NULL
together	NULL
with	NULL
the	NULL
inability	NULL
of	NULL
pol	NULL
|	NULL
to	NULL
elongate	NULL
a	NULL
DNA	NULL
chain	NULL
after	NULL
incorporating	NULL
the	NULL
incorrect	NULL
nucleotide	NULL
opposite	NULL
a	NULL
lesion	NULL
,	NULL
allows	NULL
this	NULL
polymerase	NULL
to	NULL
perform	NULL
error-free	NULL
translesion	NULL
synthesis	NULL
of	NULL
damaged	NULL
DNA	NULL
(	NULL
Johnson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999a	NULL
,	NULL
19992	NULL
,	NULL
1999b	NULL
,	NULL
2000a	NULL
;	NULL
Washington	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
;	NULL
Masutani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
;	NULL
Matsuda	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

Our	NULL
demonstration	NULL
that	NULL
BCR	NULL
engagement	NULL
upregulates	NULL
pol	NULL
and	NULL
profoundly	NULL
downregulates	NULL
pol	NULL
1	NULL
,	NULL
supports	NULL
the	NULL
speculation	NULL
that	NULL
the	NULL
lack	NULL
or	NULL
scarcity	NULL
of	NULL
pol	NULL
1	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
8	NULL
facilitates	NULL
the	NULL
insertion	NULL
of	NULL
mismatched	NULL
nucleotides	NULL
(	NULL
mutations	NULL
)	NULL
at	NULL
the	NULL
site	NULL
of	NULL
DNA	NULL
breaks	NULL
by	NULL
another	NULL
(	NULL
error-prone	NULL
)	NULL
polymerase	NULL
,	NULL
such	NULL
as	NULL
pol	NULL
t	NULL
or	NULL
pol	NULL
u	NULL
,	NULL
which	NULL
would	NULL
then	NULL
lead	NULL
to	NULL
the	NULL
extension	NULL
of	NULL
the	NULL
mutated	NULL
DNA	NULL
by	NULL
the	NULL
mispair	NULL
extender	NULL
pol	NULL
&	NULL
.	NULL

Both	NULL
pol	NULL
t	NULL
and	NULL
pol	NULL
u	NULL
have	NULL
been	NULL
suggested	NULL
to	NULL
be	NULL
preferentially	NULL
expressed	NULL
in	NULL
secondary	NULL
lymphoid	NULL
tissues	NULL
(	NULL
Aoufouchi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
;	NULL
Dominguez	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
;	NULL
Poltoratsky	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

Neither	NULL
was	NULL
downregulated	NULL
by	NULL
BCR	NULL
engagement	NULL
in	NULL
vivo	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
or	NULL
in	NULL
vitro	NULL
(	NULL
Figures	NULL
2-4	NULL
)	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
pol	NULL
&	NULL
in	NULL
the	NULL
somatic	NULL
hypermutation	NULL
process	NULL
was	NULL
demonstrated	NULL
using	NULL
specific	NULL
sense	NULL
and	NULL
antisense	NULL
phosphorothioate-modified	NULL
oligonucleotides	NULL
,	NULL
which	NULL
effectively	NULL
inhibited	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
REV3	NULL
gene	NULL
without	NULL
altering	NULL
the	NULL
expression	NULL
of	NULL
pol	NULL
,	NULL
pol	NULL
a	NULL
,	NULL
pol	NULL
B	NULL
,	NULL
pol	NULL
u	NULL
,	NULL
or	NULL
B-actin	NULL
(	NULL
Figures	NULL
4A	NULL
and	NULL
4B	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
S01	NULL
and	NULL
ASO1	NULL
but	NULL
not	NULL
ASO2	NULL
and	NULL
ASO3	NULL
to	NULL
actually	NULL
inhibit	NULL
pol	NULL
&	NULL
expression	NULL
was	NULL
highly	NULL
consistent	NULL
with	NULL
the	NULL
degree	NULL
of	NULL
effectiveness	NULL
predicted	NULL
for	NULL
these	NULL
oligonucleotides	NULL
using	NULL
the	NULL
HY	NULL
Bsimulator	NULL
(	NULL
RNAture	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

Antisense	NULL
oligonucleotides	NULL
would	NULL
disrupt	NULL
gene	NULL
expression	NULL
by	NULL
providing	NULL
a	NULL
substrate	NULL
for	NULL
RNase	NULL
H	NULL
upon	NULL
hybridization	NULL
with	NULL
mRNA	NULL
(	NULL
Gewirtz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
;	NULL
sense	NULL
oligonucleotides	NULL
would	NULL
impair	NULL
gene	NULL
transcription	NULL
by	NULL
hybridizing	NULL
with	NULL
double-strand	NULL
DNA	NULL
,	NULL
within	NULL
the	NULL
major	NULL
helix	NULL
groove	NULL
,	NULL
to	NULL
generate	NULL
a	NULL
triple-stranded	NULL
molecule	NULL
,	NULL
thereby	NULL
preventing	NULL
duplex	NULL
unwinding	NULL
(	NULL
Chan	NULL
and	NULL
Glazer	NULL
,	NULL
1997	NULL
;	NULL
Gewirtz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Praseuth	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
;	NULL
Catapano	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
;	NULL
Faria	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

The	NULL
impairment	NULL
of	NULL
UV-induced	NULL
DNA	NULL
mutagenesis	NULL
,	NULL
as	NULL
assessed	NULL
using	NULL
the	NULL
pSP189	NULL
shuttle	NULL
vector	NULL
(	NULL
Figure	NULL
4E	NULL
)	NULL
,	NULL
in	NULL
the	NULL
human	NULL
B	NULL
cells	NULL
treated	NULL
with	NULL
the	NULL
pol	NULL
£	NULL
REV3	NULL
S01	NULL
and	NULL
ASO1	NULL
but	NULL
not	NULL
the	NULL
SCRA	NULL
,	NULL
AS02	NULL
,	NULL
or	NULL
the	NULL
AS03	NULL
phosphorothioate-modified	NULL
oligonucleodites	NULL
strengthened	NULL
our	NULL
findings	NULL
on	NULL
Ig	NULL
and	NULL
be/-6	NULL
hypermutation	NULL
.	NULL

The	NULL
normal	NULL
cell	NULL
cycle	NULL
,	NULL
viability	NULL
,	NULL
and	NULL
proliferation	NULL
of	NULL
the	NULL
human	NULL
B	NULL
cells	NULL
in	NULL
which	NULL
pol	NULL
£	NULL
REV3	NULL
transcripts	NULL
were	NULL
inhibited	NULL
by	NULL
the	NULL
specific	NULL
oligonucleotides	NULL
was	NULL
evocative	NULL
of	NULL
the	NULL
findings	NULL
in	NULL
human	NULL
MSU-1.2-10A-42	NULL
fibroblasts	NULL
,	NULL
in	NULL
which	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
high	NULL
level	NULL
of	NULL
antisense	NULL
REV3	NULL
mRNA	NULL
significantly	NULL
affected	NULL
UV-induced	NULL
mutagenesis	NULL
but	NULL
not	NULL
cell	NULL
division	NULL
(	NULL
Gibbs	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

The	NULL
residual	NULL
damage-induced	NULL
mutagenic	NULL
activity	NULL
measured	NULL
in	NULL
the	NULL
B	NULL
cells	NULL
treated	NULL
with	NULL
S01	NULL
and	NULL
ASO1	NULL
was	NULL
consistent	NULL
with	NULL
the	NULL
residual	NULL
mutations	NULL
detected	NULL
in	NULL
the	NULL
Ig	NULL
VygDJy	NULL
and	NULL
be/-6	NULL
genes	NULL
of	NULL
the	NULL
same	NULL
cells	NULL
(	NULL
Figures	NULL
4C	NULL
and	NULL
4D	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
a	NULL
potential	NULL
RNA	NULL
editing	NULL
enzyme	NULL
activation-induced	NULL
(	NULL
cytidine	NULL
)	NULL
deaminase	NULL
(	NULL
AID	NULL
)	NULL
has	NULL
been	NULL
found	NULL
to	NULL
play	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
class	NULL
switching	NULL
and	NULL
Ig	NULL
somatic	NULL
hypermutation	NULL
(	NULL
Muramatsu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
;	NULL
Revy	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

In	NULL
AID-deficient	NULL
mice	NULL
and	NULL
patients	NULL
with	NULL
defective	NULL
AID	NULL
function	NULL
,	NULL
Ig	NULL
somatic	NULL
hypermutation	NULL
appears	NULL
to	NULL
be	NULL
defective	NULL
(	NULL
Muramatsu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
;	NULL
Revy	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
,	NULL
but	NULL
the	NULL
role	NULL
of	NULL
AID	NULL
in	NULL
the	NULL
somatic	NULL
hypermutation	NULL
process	NULL
in	NULL
unclear	NULL
and	NULL
possibly	NULL
indirect	NULL
.	NULL

The	NULL
most	NULL
likely	NULL
targets	NULL
for	NULL
AID	NULL
could	NULL
be	NULL
any	NULL
of	NULL
the	NULL
DNA	NULL
enzymes	NULL
that	NULL
would	NULL
be	NULL
involved	NULL
in	NULL
somatic	NULL
hypermutation	NULL
,	NULL
including	NULL
pol	NULL
&	NULL
and	NULL
perhaps	NULL
an	NULL
endonuclease	NULL
that	NULL
creates	NULL
a	NULL
single-strand	NULL
nick	NULL
or	NULL
a	NULL
double-strand	NULL
cut	NULL
.	NULL

Thus	NULL
,	NULL
pol	NULL
&	NULL
and	NULL
AID	NULL
would	NULL
represent	NULL
different	NULL
elements	NULL
with	NULL
different	NULL
functions	NULL
in	NULL
the	NULL
somatic	NULL
hypermutation	NULL
process	NULL
,	NULL
which	NULL
would	NULL
also	NULL
include	NULL
,	NULL
as	NULL
suggested	NULL
by	NULL
our	NULL
experiments	NULL
,	NULL
a	NULL
role	NULL
for	NULL
the	NULL
modulation	NULL
of	NULL
pol	NULL
n.	NULL
Whether	NULL
pol	NULL
1	NULL
,	NULL
overexpression	NULL
affects	NULL
Ig	NULL
somatic	NULL
hypermutation	NULL
and	NULL
whether	NULL
AID	NULL
expression	NULL
is	NULL
,	NULL
like	NULL
pol	NULL
&	NULL
and	NULL
pol	NULL
11	NULL
,	NULL
under	NULL
the	NULL
control	NULL
of	NULL
signals	NULL
emanating	NULL
from	NULL
the	NULL
BCR	NULL
is	NULL
currently	NULL
being	NULL
investigated	NULL
in	NULL
our	NULL
laboratory	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
9	NULL
Experimental	NULL
Procedures	NULL
Lymphocytes	NULL
The	NULL
phenotypic	NULL
and	NULL
functional	NULL
features	NULL
of	NULL
the	NULL
human	NULL
monoclonal	NULL
IgM	NULL
'IgD*	NULL
CL-O1	NULL
B	NULL
cell	NULL
line	NULL
were	NULL
reported	NULL
(	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
,	NULL
1999	NULL
,	NULL
2000a	NULL
;	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998a	NULL
,	NULL
1998b	NULL
,	NULL
2000	NULL
;	NULL
Schaffer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

To	NULL
prepare	NULL
sIgD*	NULL
B	NULL
cells	NULL
,	NULL
human	NULL
PBMCs	NULL
were	NULL
depleted	NULL
of	NULL
T	NULL
cells	NULL
(	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998b	NULL
)	NULL
,	NULL
reacted	NULL
with	NULL
a	NULL
mouse	NULL
mAb	NULL
to	NULL
human	NULL
IgD	NULL
(	NULL
Southern	NULL
Biotechnology	NULL
Associates	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
and	NULL
then	NULL
with	NULL
magnetic	NULL
Microbeads	NULL
conjugated	NULL
with	NULL
goat	NULL
anti-mouse	NULL
IgG	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

The	NULL
Microbead-treated	NULL
sIgD*	NULL
B	NULL
cells	NULL
were	NULL
separated	NULL
using	NULL
a	NULL
MACS	NULL
magnetic	NULL
sorter	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

Tonsillar	NULL
IgD*CD38~	NULL
,	NULL
IgD*CD38*	NULL
,	NULL
IgD	NULL
-	NULL
CD38+	NULL
,	NULL
and	NULL
IgD~CD38~	NULL
B	NULL
cells	NULL
were	NULL
selected	NULL
upon	NULL
incubation	NULL
of	NULL
purified	NULL
IgD*	NULL
B	NULL
cells	NULL
with	NULL
MultiSort	NULL
Release	NULL
Reagent	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
FITC-conjugated	NULL
mouse	NULL
mAb	NULL
to	NULL
CD38	NULL
(	NULL
PharMingen	NULL
)	NULL
,	NULL
and	NULL
anti-FITC	NULL
MicroBeads	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
as	NULL
reported	NULL
(	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

The	NULL
homogeneity	NULL
of	NULL
the	NULL
separated	NULL
cell	NULL
fractions	NULL
was	NULL
assessed	NULL
using	NULL
a	NULL
FACScalibur	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

The	NULL
human	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
used	NULL
for	NULL
the	NULL
hypermutation	NULL
induction	NULL
experiments	NULL
were	NULL
prepared	NULL
as	NULL
reported	NULL
(	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
,	NULL
20002	NULL
)	NULL
.	NULL

Human	NULL
DNA	NULL
pol	NULL
C	NULL
,	NULL
pol	NULL
n	NULL
,	NULL
pol	NULL
1	NULL
,	NULL
pol	NULL
a	NULL
,	NULL
pol	NULL
B	NULL
,	NULL
pol	NULL
&	NULL
,	NULL
pol	NULL
e	NULL
,	NULL
pol	NULL
x	NULL
,	NULL
and	NULL
pol	NULL
u	NULL
Transcripts	NULL
The	NULL
level	NULL
of	NULL
pol	NULL
&	NULL
,	NULL
pol	NULL
1	NULL
(	NULL
RAD30A	NULL
)	NULL
,	NULL
pol	NULL
v	NULL
(	NULL
RAD3OB	NULL
)	NULL
,	NULL
pol	NULL
a	NULL
,	NULL
pol	NULL
B	NULL
,	NULL
pol	NULL
8	NULL
,	NULL
pol	NULL
s	NULL
,	NULL
pol	NULL
x	NULL
,	NULL
and	NULL
pol	NULL
u	NULL
was	NULL
analyzed	NULL
by	NULL
RT-PCR	NULL
.	NULL

This	NULL
was	NULL
made	NULL
semiquantitative	NULL
by	NULL
performing	NULL
dilution	NULL
analysis	NULL
so	NULL
that	NULL
there	NULL
was	NULL
a	NULL
linear	NULL
relationship	NULL
between	NULL
the	NULL
amount	NULL
of	NULL
cDNA	NULL
used	NULL
and	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
PCR	NULL
product	NULL
.	NULL

Each	NULL
PCR	NULL
consisted	NULL
of	NULL
25	NULL
cycles	NULL
,	NULL
each	NULL
of	NULL
1	NULL
min	NULL
denaturation	NULL
at	NULL
94°C	NULL
,	NULL
1	NULL
min	NULL
annealing	NULL
at	NULL
60°C	NULL
,	NULL
and	NULL
1	NULL
min	NULL
extension	NULL
at	NULL
72°C	NULL
.	NULL

The	NULL
amplifications	NULL
were	NULL
completed	NULL
by	NULL
an	NULL
additional	NULL
10	NULL
min	NULL
extension	NULL
at	NULL
72°C	NULL
.	NULL

RT-PCR	NULL
using	NULL
[	NULL
a-	NULL
``	NULL
``	NULL
P	NULL
]	NULL
dCTP	NULL
consisted	NULL
of	NULL
10	NULL
,	NULL
15	NULL
,	NULL
and	NULL
25	NULL
cycles	NULL
.	NULL

RNA	NULL
was	NULL
extracted	NULL
from	NULL
2	NULL
x	NULL
10°	NULL
B	NULL
cells	NULL
,	NULL
using	NULL
the	NULL
RNeasy	NULL
Mini	NULL
Kit	NULL
(	NULL
Qiagen	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

The	NULL
first-strand	NULL
cDNAs	NULL
were	NULL
synthesized	NULL
from	NULL
equal	NULL
amounts	NULL
of	NULL
total	NULL
RNAs	NULL
(	NULL
4	NULL
ug	NULL
)	NULL
,	NULL
using	NULL
the	NULL
SuperScript	NULL
Preamplification	NULL
System	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

The	NULL
different	NULL
cDNAs	NULL
were	NULL
amplified	NULL
using	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
first-strand	NULL
cDNA	NULL
template	NULL
together	NULL
with	NULL
the	NULL
following	NULL
specific	NULL
primers	NULL
:	NULL
pol	NULL
{	NULL
REV3	NULL
,	NULL
5	NULL
``	NULL
-GAGATTCAGATGCATTCCTGG-3	NULL
'	NULL
(	NULL
forward	NULL
)	NULL
,	NULL
5-GTCTTGCTTGTAAGCCTTCAT-3	NULL
'	NULL
(	NULL
reverse	NULL
)	NULL
,	NULL
or	NULL
5-GTTGCTTTGAT	NULL
CGACACATCCC-3	NULL
``	NULL
'	NULL
(	NULL
for2	NULL
)	NULL
,	NULL
5	NULL
``	NULL
-GAGGTTTTCAGTGCTCCTTCCAC-3	NULL
(	NULL
rev	NULL
)	NULL
,	NULL
5-ATGTGGACATCCTGCTCATCCG-3	NULL
(	NULL
rev2	NULL
)	NULL
;	NULL
pol	NULL
n	NULL
,	NULL
5	NULL
!	NULL

-CGAAATGATAATGACAGGGTAGCC-3	NULL
'	NULL
(	NULL
for	NULL
)	NULL
,	NULL
5	NULL
``	NULL
-GGAGCAGTAAGAGATGAAAGCGAAG-3	NULL
'	NULL
(	NULL
rev	NULL
)	NULL
;	NULL
pol	NULL
u	NULL
,	NULL
5	NULL
``	NULL
-TTGCTTTAGGGCTCAAGGGTG-3	NULL
'	NULL
(	NULL
for	NULL
)	NULL
,	NULL
5-TTCACATAAGTAAGGCTGGCGG-3	NULL
'	NULL
(	NULL
rev	NULL
)	NULL
;	NULL
pol	NULL
a	NULL
,	NULL
5	NULL
!	NULL

-AAGCACATCTTGACCCAGAGGAGC-3	NULL
'	NULL
(	NULL
for	NULL
)	NULL
,	NULL
5	NULL
``	NULL
-CAGAGAACAGCAGAGGACAGA	NULL
AGC-3	NULL
'	NULL
(	NULL
rev	NULL
)	NULL
;	NULL
pol	NULL
B	NULL
,	NULL
5	NULL
``	NULL
-AAGATTCGGCAGGATGATACGAG-3	NULL
'	NULL
(	NULL
for	NULL
)	NULL
,	NULL
5	NULL
``	NULL
-AACACCCATGAACTTTGTCTCACC-3	NULL
'	NULL
(	NULL
rev	NULL
)	NULL
;	NULL
pol	NULL
8	NULL
,	NULL
5'-GCCAGCAGGTCAAAGTCGTATC-3	NULL
'	NULL
(	NULL
for	NULL
)	NULL
,	NULL
5-GCACTGAGGTCTTCACAAACTCG-4	NULL
(	NULL
rev	NULL
)	NULL
;	NULL
pol	NULL
s	NULL
,	NULL
5-GATGAGGAGGAAAGAGATGGGG-3	NULL
'	NULL
(	NULL
for	NULL
)	NULL
,	NULL
5	NULL
``	NULL
-GGGTTATTGAGCAGCAAGTGGG-3	NULL
'	NULL
(	NULL
rev	NULL
)	NULL
;	NULL
pol	NULL
x	NULL
,	NULL
5	NULL
``	NULL
-TTGCTTTAGGGCTCAAGGGTG-3	NULL
'	NULL
(	NULL
for	NULL
)	NULL
,	NULL
5-TTCACATAAGTAAGGCTGGCGG-3	NULL
'	NULL
(	NULL
rev	NULL
)	NULL
;	NULL
pol	NULL
u	NULL
,	NULL
5-GCCTGTTCTCAGCACAATGTCTC-3	NULL
``	NULL
'	NULL
(	NULL
for	NULL
)	NULL
,	NULL
5	NULL
``	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
10	NULL
GTCTGGGAAATCCTCGCCTAAC-3	NULL
``	NULL
'	NULL
(	NULL
rev	NULL
)	NULL
.	NULL

In	NULL
selected	NULL
experiments	NULL
,	NULL
RT-PCR	NULL
for	NULL
pol	NULL
£	NULL
REV3	NULL
,	NULL
pol	NULL
11	NULL
,	NULL
and	NULL
B-actin	NULL
were	NULL
performed	NULL
in	NULL
the	NULL
same	NULL
vessel	NULL
.	NULL

Induction	NULL
of	NULL
Somatic	NULL
Hypermutation	NULL
in	NULL
Human	NULL
B	NULL
Cells	NULL
To	NULL
induce	NULL
Ig	NULL
hypermutation	NULL
,	NULL
human	NULL
IgM	NULL
*IgD*	NULL
CL-O1	NULL
B	NULL
cells	NULL
(	NULL
0.5	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
reacted	NULL
for	NULL
1	NULL
hr	NULL
at	NULL
4°C	NULL
with	NULL
IMMUNOBEAD-conjugated	NULL
rabbit	NULL
Ab	NULL
to	NULL
human	NULL
Ig	NULL
m	NULL
chain	NULL
and	NULL
rabbit	NULL
Ab	NULL
to	NULL
human	NULL
Ig	NULL
(	NULL
H	NULL
+	NULL
L	NULL
chain	NULL
)	NULL
(	NULL
Irvine	NULL
Scientific	NULL
)	NULL
(	NULL
mixed	NULL
1:1	NULL
at	NULL
1	NULL
ug/ml	NULL
!	NULL
)	NULL

(	NULL
anti-BCR	NULL
Ab	NULL
)	NULL
,	NULL
and	NULL
then	NULL
washed	NULL
with	NULL
cold	NULL
PBS	NULL
before	NULL
being	NULL
placed	NULL
in	NULL
culture	NULL
with	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
used	NULL
at	NULL
least	NULL
2	NULL
weeks	NULL
from	NULL
the	NULL
last	NULL
stimulation	NULL
and	NULL
were	NULL
incubated	NULL
for	NULL
6	NULL
hr	NULL
with	NULL
20	NULL
ng/ml	NULL
of	NULL
13-phorbol	NULL
12-myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
and	NULL
500	NULL
ng/m	NULL
!	NULL

of	NULL
ionomycin	NULL
(	NULL
Calbiochem-Novabiochem	NULL
Co.	NULL
)	NULL
prior	NULL
to	NULL
coculture	NULL
with	NULL
B	NULL
cells	NULL
(	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
,	NULL
2000a	NULL
)	NULL
.	NULL

B	NULL
cells	NULL
were	NULL
cocultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2.5	NULL
x	NULL
10°	NULL
irradiated	NULL
and	NULL
activated	NULL
CD4	NULL
T	NULL
cells	NULL
or	NULL
nil	NULL
in	NULL
a	NULL
flat-bottom	NULL
6-well	NULL
(	NULL
5.0	NULL
ml	NULL
FCS-RPMI	NULL
volume	NULL
)	NULL
plate	NULL
.	NULL

After	NULL
7	NULL
days	NULL
of	NULL
culture	NULL
during	NULL
which	NULL
fresh	NULL
anti-BCR	NULL
Ab	NULL
was	NULL
added	NULL
every	NULL
other	NULL
day	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.1	NULL
ug/ml	NULL
,	NULL
the	NULL
lymphocytes	NULL
were	NULL
washed	NULL
in	NULL
fresh	NULL
FCS-RPMI	NULL
and	NULL
then	NULL
supplemented	NULL
with	NULL
freshly	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

After	NULL
additional	NULL
7	NULL
days	NULL
of	NULL
similar	NULL
treatment	NULL
,	NULL
the	NULL
cultures	NULL
were	NULL
terminated	NULL
.	NULL

At	NULL
12	NULL
hr	NULL
,	NULL
1	NULL
day	NULL
,	NULL
2	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
9	NULL
,	NULL
and	NULL
14	NULL
days	NULL
from	NULL
the	NULL
initiation	NULL
of	NULL
the	NULL
culture	NULL
,	NULL
the	NULL
B	NULL
cells	NULL
were	NULL
purified	NULL
by	NULL
positive	NULL
selection	NULL
with	NULL
a	NULL
biotinylated	NULL
anti-CD19	NULL
mAb	NULL
and	NULL
MiniMac	NULL
System	NULL
Streptavidin	NULL
microbeads	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
,	NULL
Inc.	NULL
)	NULL
and	NULL
used	NULL
as	NULL
a	NULL
source	NULL
of	NULL
mRNA	NULL
for	NULL
the	NULL
analysis	NULL
of	NULL
DNA	NULL
polymerases	NULL
and	NULL
Ig	NULL
V	NULL
(	NULL
D	NULL
)	NULL
J	NULL
and	NULL
be/-6	NULL
mutations	NULL
.	NULL

Analysis	NULL
of	NULL
Mutated	NULL
Ig	NULL
VpDJp	NULL
and	NULL
bel-6	NULL
Transcripts	NULL
The	NULL
VgDJy	NULL
and	NULL
be/-6	NULL
transcripts	NULL
were	NULL
amplified	NULL
by	NULL
RT-PCR	NULL
using	NULL
the	NULL
Pfu	NULL
Turbo	NULL
DNA	NULL
polymerase	NULL
(	NULL
Stratagene	NULL
)	NULL
(	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
,	NULL
2000a	NULL
)	NULL
.	NULL

cDNAs	NULL
were	NULL
purified	NULL
using	NULL
the	NULL
QIAquick	NULL
PCR	NULL
purification	NULL
kit	NULL
(	NULL
Qiagen	NULL
)	NULL
and	NULL
cloned	NULL
into	NULL
pCR-Blunt	NULL
II	NULL
TOPO	NULL
(	NULL
Zero	NULL
Blunt	NULL
TOPO	NULL
PCR	NULL
Cloning	NULL
kit	NULL
,	NULL
Invitrogen	NULL
)	NULL
.	NULL

Mutated	NULL
VgDJy	NULL
transcripts	NULL
were	NULL
identified	NULL
by	NULL
SSCP	NULL
analysis	NULL
and	NULL
then	NULL
sequenced	NULL
(	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
,	NULL
20002	NULL
)	NULL
.	NULL

Identical	NULL
somatic	NULL
point	NULL
mutations	NULL
were	NULL
counted	NULL
only	NULL
once	NULL
,	NULL
on	NULL
the	NULL
assumption	NULL
that	NULL
they	NULL
were	NULL
due	NULL
to	NULL
the	NULL
same	NULL
mutational	NULL
events	NULL
(	NULL
shared	NULL
mutations	NULL
)	NULL
,	NULL
although	NULL
some	NULL
of	NULL
these	NULL
mutations	NULL
might	NULL
have	NULL
arisen	NULL
independently	NULL
.	NULL

The	NULL
expected	NULL
frequency	NULL
of	NULL
mutations	NULL
from	NULL
one	NULL
base	NULL
to	NULL
the	NULL
other	NULL
three	NULL
was	NULL
calculated	NULL
by	NULL
assuming	NULL
randomness	NULL
.	NULL

The	NULL
comparisons	NULL
of	NULL
the	NULL
observed	NULL
with	NULL
the	NULL
expected	NULL
number	NULL
of	NULL
mutations	NULL
were	NULL
performed	NULL
using	NULL
a	NULL
contingency	NULL
table	NULL
(	NULL
x	NULL
>	NULL
test	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
pol	NULL
€	NULL
Expression	NULL
,	NULL
Ig	NULL
,	NULL
and	NULL
be/-6	NULL
Somatic	NULL
Hypermutation	NULL
and	NULL
UV	NULL
Damage-Induced	NULL
Mutagenesis	NULL
by	NULL
Specific	NULL
pol	NULL
(	NULL
REV3	NULL
Oligonucleotides	NULL
The	NULL
specific	NULL
pol	NULL
&	NULL
REV3	NULL
phosphorothioate-modified	NULL
oligodeoxynucleotides	NULL
were	NULL
designed	NULL
by	NULL
RNAture	NULL
,	NULL
Inc.	NULL
,	NULL
using	NULL
the	NULL
proprietary	NULL
HYBsimulator	NULL
``	NULL
Antisense	NULL
Strategy	NULL
,	NULL
``	NULL
and	NULL
were	NULL
synthesized	NULL
by	NULL
GenBase	NULL
,	NULL
Inc.	NULL
S01	NULL
(	NULL
5-GACTTATGTCGGATG-3	NULL
'	NULL
)	NULL
was	NULL
identical	NULL
to	NULL
and	NULL
ASO1	NULL
(	NULL
5-CATCCGACATAAGTC-3	NULL
``	NULL
)	NULL
was	NULL
the	NULL
reverse	NULL
complement	NULL
of	NULL
the	NULL
15	NULL
nucleotides	NULL
7301-7315	NULL
of	NULL
the	NULL
human	NULL
pol	NULL
£	NULL
REV3	NULL
mRNA	NULL
sequence	NULL
(	NULL
GenBank	NULL
number	NULL
AF157476	NULL
)	NULL
.	NULL

SCRA	NULL
oligodeoxynucleotide	NULL
consisted	NULL
of	NULL
the	NULL
same	NULL
bases	NULL
as	NULL
ASO1	NULL
but	NULL
in	NULL
a	NULL
scrambled	NULL
order	NULL
.	NULL

The	NULL
AS02	NULL
(	NULL
5'-ACTCTGTGGTTCAAC-3	NULL
'	NULL
)	NULL
and	NULL
AS03	NULL
(	NULL
5	NULL
``	NULL
-	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
11	NULL
TGACGTATGGCACTC-3	NULL
'	NULL
)	NULL
were	NULL
the	NULL
reverse	NULL
complements	NULL
of	NULL
the	NULL
15	NULL
nucleotides	NULL
713-727	NULL
and	NULL
8874-8888	NULL
residues	NULL
of	NULL
the	NULL
human	NULL
pol	NULL
£	NULL
REV3	NULL
mRNA	NULL
sequence	NULL
.	NULL

The	NULL
phosphorothioate-modified	NULL
oligodeoxynucleotides	NULL
were	NULL
introduced	NULL
into	NULL
CL-01	NULL
cells	NULL
using	NULL
Cytofectin	NULL
GSV	NULL
(	NULL
Glen	NULL
Research	NULL
Corp.	NULL
)	NULL
(	NULL
Lewis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Oligodeoxynucleotides	NULL
(	NULL
50	NULL
uM	NULL
)	NULL
and	NULL
Cytofectin	NULL
GSV	NULL
(	NULL
25	NULL
ug/ml	NULL
)	NULL
were	NULL
allowed	NULL
to	NULL
associate	NULL
in	NULL
250	NULL
ul	NULL
Opti-MEM	NULL
media	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
oligonucleotides/	NULL
Cytofectin	NULL
GSV	NULL
mixture	NULL
was	NULL
supplemented	NULL
with	NULL
FCS-RPMI	NULL
to	NULL
yield	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
2.5	NULL
ml	NULL
.	NULL

The	NULL
resulting	NULL
mixture	NULL
was	NULL
then	NULL
added	NULL
to	NULL
0.5	NULL
x	NULL
10°	NULL
CL-O01	NULL
cells	NULL
in	NULL
a	NULL
flat-bottom	NULL
6-well	NULL
plate	NULL
which	NULL
was	NULL
incubated	NULL
for	NULL
24	NULL
hr	NULL
at	NULL
37°C	NULL
.	NULL

After	NULL
incubation	NULL
,	NULL
the	NULL
B	NULL
cells	NULL
were	NULL
reacted	NULL
with	NULL
anti-BCR	NULL
Ab	NULL
and	NULL
then	NULL
cocultured	NULL
with	NULL
CD4*	NULL
T	NULL
cells	NULL
for	NULL
a	NULL
cycle	NULL
of	NULL
14	NULL
days	NULL
,	NULL
as	NULL
outlined	NULL
above	NULL
,	NULL
with	NULL
the	NULL
oligonucleotides/Cytofectin	NULL
GSV	NULL
treatment	NULL
being	NULL
repeated	NULL
every	NULL
24	NULL
hr	NULL
.	NULL

B	NULL
cells	NULL
were	NULL
purified	NULL
after	NULL
1	NULL
,	NULL
2	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
9	NULL
,	NULL
and	NULL
14	NULL
days	NULL
by	NULL
positive	NULL
selection	NULL
with	NULL
a	NULL
biotinylated	NULL
anti-CD19	NULL
mAb	NULL
and	NULL
MiniMac	NULL
System	NULL
Streptavidin	NULL
microbeads	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
,	NULL
Inc.	NULL
)	NULL
for	NULL
the	NULL
the	NULL
analysis	NULL
of	NULL
the	NULL
DNA	NULL
polymerases	NULL
and	NULL
the	NULL
Ig	NULL
VgDJy	NULL
and	NULL
be/-6	NULL
transcripts	NULL
.	NULL

At	NULL
the	NULL
same	NULL
time	NULL
points	NULL
,	NULL
the	NULL
same	NULL
and	NULL
similar	NULL
cultures	NULL
were	NULL
analyzed	NULL
for	NULL
cell	NULL
number	NULL
,	NULL
viability	NULL
(	NULL
trypan	NULL
blue	NULL
exclusion	NULL
)	NULL
,	NULL
and	NULL
cycle	NULL
,	NULL
using	NULL
propidium	NULL
iodide	NULL
(	NULL
PI	NULL
)	NULL
and	NULL
fluorescence	NULL
flow	NULL
cytometry	NULL
(	NULL
Noguchi	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

Damage-induced	NULL
DNA	NULL
mutagenesis	NULL
was	NULL
analyzed	NULL
essentially	NULL
as	NULL
reported	NULL
by	NULL
Seidman	NULL
(	NULL
Seidman	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
CL-O1	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
Cytofectin	NULL
GSV	NULL
only	NULL
or	NULL
with	NULL
Cytofectin	NULL
GSV	NULL
and	NULL
the	NULL
pol	NULL
£	NULL
REV3	NULL
S01	NULL
,	NULL
AS01	NULL
,	NULL
SCRA	NULL
,	NULL
ASO2	NULL
,	NULL
and	NULL
AS03	NULL
oligonucleotides	NULL
daily	NULL
for	NULL
3	NULL
days	NULL
and	NULL
transfected	NULL
with	NULL
the	NULL
UV-irradiated	NULL
(	NULL
500	NULL
J/m	NULL
)	NULL
pSP189	NULL
shuttle	NULL
vector	NULL
on	NULL
day	NULL
4	NULL
.	NULL

After	NULL
2	NULL
more	NULL
days	NULL
of	NULL
culture	NULL
,	NULL
the	NULL
plasmid	NULL
DNA	NULL
was	NULL
recovered	NULL
,	NULL
digested	NULL
with	NULL
Dpr	NULL
I	NULL
,	NULL
and	NULL
used	NULL
to	NULL
transform	NULL
E.	NULL
Coli	NULL
MBM	NULL
7070	NULL
test	NULL
strain	NULL
.	NULL

The	NULL
frequency	NULL
of	NULL
white	NULL
(	NULL
mutated	NULL
)	NULL
colonies	NULL
was	NULL
taken	NULL
as	NULL
measure	NULL
of	NULL
B	NULL
cell	NULL
mutagenic	NULL
activity	NULL
.	NULL

Supplementary	NULL
Material	NULL
Refer	NULL
to	NULL
Web	NULL
version	NULL
on	NULL
PubMed	NULL
Central	NULL
for	NULL
supplementary	NULL
material	NULL
.	NULL

Acknowledgments	NULL
We	NULL
are	NULL
grateful	NULL
to	NULL
Dr.	NULL
William	NULL
K.	NULL
Holloman	NULL
for	NULL
helpful	NULL
discussions	NULL
and	NULL
to	NULL
Dr.	NULL
Michael	NULL
M.	NULL
Seidman	NULL
for	NULL
the	NULL
shuttle	NULL
vector	NULL
pSP189	NULL
and	NULL
the	NULL
test	NULL
£	NULL
.	NULL

Coli	NULL
strain	NULL
MBM7070	NULL
.	NULL

We	NULL
thank	NULL
Shefali	NULL
Shah	NULL
and	NULL
Pat	NULL
Dramitinos	NULL
for	NULL
their	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
grants	NULL
AR	NULL
40908	NULL
,	NULL
AG	NULL
13910	NULL
,	NULL
and	NULL
Al	NULL
45011	NULL
and	NULL
by	NULL
a	NULL
Research	NULL
Grant	NULL
from	NULL
the	NULL
SLE	NULL
Foundation	NULL
,	NULL
Inc.	NULL
(	NULL
New	NULL
York	NULL
)	NULL
(	NULL
to	NULL
P.C	NULL
.	NULL
)	NULL

.	NULL

A.S.	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
Cancer	NULL
Research	NULL
Institute	NULL
(	NULL
New	NULL
York	NULL
)	NULL
fellowship	NULL
.	NULL

References	NULL
Aoufouchi	NULL
S	NULL
,	NULL
Flatter	NULL
E	NULL
,	NULL
Dahan	NULL
A	NULL
,	NULL
Faili	NULL
A	NULL
,	NULL
Bertocci	NULL
B	NULL
,	NULL
Storck	NULL
S	NULL
,	NULL
Delbos	NULL
F	NULL
,	NULL
Cocea	NULL
L	NULL
,	NULL
Gupta	NULL
N	NULL
,	NULL
Weill	NULL
JC	NULL
,	NULL
Reynaud	NULL
CA	NULL
.	NULL

Two	NULL
novel	NULL
human	NULL
and	NULL
mouse	NULL
DNA	NULL
polymerases	NULL
of	NULL
the	NULL
pol	NULL
X	NULL
family	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

2000	NULL
;	NULL
28:3684-3693	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10982892	NULL
]	NULL
Bach	NULL
]	NULL
J	NULL
,	NULL
Wabl	NULL
M.	NULL
Hypermutation	NULL
in	NULL
T	NULL
cells	NULL
questioned	NULL
.	NULL

Nature	NULL
.	NULL

1995	NULL
;	NULL
375:285-286	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7753192	NULL
]	NULL
Bebenek	NULL
K	NULL
,	NULL
Matsuda	NULL
T	NULL
,	NULL
Masutani	NULL
C	NULL
,	NULL
Hanaoka	NULL
F	NULL
,	NULL
Kunkel	NULL
TA	NULL
.	NULL

Proofreading	NULL
of	NULL
DNA	NULL
polymerase	NULL
n-dependent	NULL
replication	NULL
errors	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

2001	NULL
;	NULL
276:2317-2320	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
11113111	NULL
]	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
12	NULL
Bemark	NULL
M	NULL
,	NULL
Khamlichi	NULL
AA	NULL
,	NULL
Davies	NULL
SL	NULL
,	NULL
Neuberger	NULL
MS.	NULL
Disruption	NULL
of	NULL
mouse	NULL
polymerase	NULL
zeta	NULL
(	NULL
Rev3	NULL
)	NULL
leads	NULL
to	NULL
embryonic	NULL
lethality	NULL
and	NULL
impairs	NULL
blastocyst	NULL
development	NULL
in	NULL
vitro	NULL
.	NULL

Curr	NULL
.	NULL

Biol	NULL
.	NULL

2000	NULL
;	NULL
10:1213-1216	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
11050391	NULL
]	NULL
Bertocci	NULL
B	NULL
,	NULL
Quint	NULL
L	NULL
,	NULL
Delbos	NULL
F	NULL
,	NULL
Garcia	NULL
C	NULL
,	NULL
Reynaud	NULL
CA	NULL
,	NULL
Weill	NULL
JC	NULL
.	NULL

Probing	NULL
immunoglobulin	NULL
gene	NULL
hypermutation	NULL
with	NULL
microsatellites	NULL
suggests	NULL
a	NULL
nonreplicative	NULL
short	NULL
patch	NULL
DNA	NULL
synthesis	NULL
process	NULL
.	NULL

Immunity	NULL
.	NULL

1998	NULL
;	NULL
9:257-265	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9729046	NULL
]	NULL
Bross	NULL
L	NULL
,	NULL
Fukita	NULL
Y	NULL
,	NULL
McBlane	NULL
F	NULL
,	NULL
Demolliere	NULL
C	NULL
,	NULL
Rajewsky	NULL
K	NULL
,	NULL
Jacobs	NULL
H.	NULL
DNA	NULL
double-strand	NULL
breaks	NULL
in	NULL
immunoglobulin	NULL
genes	NULL
undergoing	NULL
somatic	NULL
hypermutation	NULL
.	NULL

Immunity	NULL
.	NULL

2000	NULL
;	NULL
13:589-597	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
11114372	NULL
]	NULL
Burgers	NULL
PM	NULL
.	NULL

Eukaryotic	NULL
DNA	NULL
polymerases	NULL
in	NULL
DNA	NULL
replication	NULL
and	NULL
DNA	NULL
repair	NULL
.	NULL

Chromosoma	NULL
.	NULL

1998	NULL
;	NULL
107:218-227	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9745046	NULL
]	NULL
Catapano	NULL
CV	NULL
,	NULL
McGuffie	NULL
EM	NULL
,	NULL
Pacheco	NULL
D	NULL
,	NULL
Carbone	NULL
GM	NULL
.	NULL

Inhibition	NULL
of	NULL
gene	NULL
expression	NULL
and	NULL
cell	NULL
proliferation	NULL
by	NULL
triple	NULL
helix-forming	NULL
oligonucleotides	NULL
directed	NULL
to	NULL
the	NULL
c-myc	NULL
gene	NULL
.	NULL

Biochemistry	NULL
.	NULL

2000	NULL
;	NULL
39:5126-5138	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10819980	NULL
]	NULL
Cerutti	NULL
A	NULL
,	NULL
Zan	NULL
H	NULL
,	NULL
Schaffer	NULL
A	NULL
,	NULL
Bergsagel	NULL
L	NULL
,	NULL
Harindranath	NULL
N	NULL
,	NULL
Max	NULL
EE	NULL
,	NULL
Casali	NULL
P.	NULL
CD40	NULL
ligand	NULL
and	NULL
appropriate	NULL
cytokines	NULL
induce	NULL
switching	NULL
to	NULL
IgG	NULL
,	NULL
IgA	NULL
,	NULL
and	NULL
IgE	NULL
and	NULL
coordinated	NULL
germinal	NULL
center	NULL
and	NULL
plasmacytoid	NULL
phenotypic	NULL
differentiation	NULL
in	NULL
a	NULL
human	NULL
monoclonal	NULL
IgM	NULL
*	NULL
IgD*	NULL
B	NULL
cell	NULL
line	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

1998a	NULL
;	NULL
160:2145-2157	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9498752	NULL
]	NULL
Cerutti	NULL
A	NULL
,	NULL
Schaffer	NULL
A	NULL
,	NULL
Shah	NULL
S	NULL
,	NULL
Zan	NULL
H	NULL
,	NULL
Liou	NULL
HC	NULL
,	NULL
Goodwin	NULL
RG	NULL
,	NULL
Casali	NULL
P.	NULL
CD30	NULL
is	NULL
a	NULL
CD4O-inducible	NULL
molecule	NULL
that	NULL
negatively	NULL
regulates	NULL
CD4O0-mediated	NULL
immunoglobulin	NULL
class	NULL
switching	NULL
in	NULL
non-antigen-selected	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

Immunity	NULL
.	NULL

1998b	NULL
;	NULL
9:247-256	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9729045	NULL
]	NULL
Cerutti	NULL
A	NULL
,	NULL
Schaffer	NULL
A	NULL
,	NULL
Shah	NULL
S	NULL
,	NULL
Goodwin	NULL
RG	NULL
,	NULL
Zan	NULL
H	NULL
,	NULL
Ely	NULL
S	NULL
,	NULL
Casali	NULL
P.	NULL
Engagement	NULL
of	NULL
CD153	NULL
(	NULL
CD30	NULL
ligand	NULL
)	NULL
by	NULL
CD30*	NULL
T	NULL
cells	NULL
inhibits	NULL
class	NULL
switch	NULL
DNA	NULL
recombination	NULL
and	NULL
antibody	NULL
production	NULL
in	NULL
human	NULL
IgDJr	NULL
IgM+	NULL
B	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

2000	NULL
;	NULL
165:786-794	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10878352	NULL
]	NULL
Chan	NULL
PP	NULL
,	NULL
Glazer	NULL
PM	NULL
.	NULL

Triplex	NULL
DNA	NULL
:	NULL
fundamentals	NULL
,	NULL
advances	NULL
,	NULL
and	NULL
potential	NULL
applications	NULL
for	NULL
gene	NULL
therapy	NULL
.	NULL

J.	NULL
Mol	NULL
.	NULL

Med	NULL
.	NULL

1997	NULL
;	NULL
75:267-282	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9151213	NULL
]	NULL
Chang	NULL
B	NULL
,	NULL
Casali	NULL
P.	NULL
The	NULL
CDR1	NULL
sequences	NULL
of	NULL
a	NULL
major	NULL
proportion	NULL
of	NULL
human	NULL
germline	NULL
Ig	NULL
V	NULL
;	NULL
genes	NULL
are	NULL
inherently	NULL
susceptible	NULL
to	NULL
amino	NULL
acid	NULL
replacement	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
.	NULL

1994	NULL
;	NULL
15:367-373	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7916950	NULL
]	NULL
Datta	NULL
A	NULL
,	NULL
Jinks-Robertson	NULL
S.	NULL
Association	NULL
of	NULL
increased	NULL
spontaneous	NULL
mutation	NULL
rates	NULL
with	NULL
high	NULL
levels	NULL
of	NULL
transcription	NULL
in	NULL
yeast	NULL
.	NULL

Science	NULL
.	NULL

1995	NULL
;	NULL
268:1616-1619	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7777859	NULL
]	NULL
Diaz	NULL
M	NULL
,	NULL
Flajnik	NULL
M.	NULL
Evolution	NULL
of	NULL
somatic	NULL
hypermutation	NULL
and	NULL
gene	NULL
conversion	NULL
in	NULL
adaptive	NULL
immunity	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

1998	NULL
;	NULL
162:13-24	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9602348	NULL
]	NULL
Dominguez	NULL
O	NULL
,	NULL
Ruiz	NULL
JF	NULL
,	NULL
Lain	NULL
de	NULL
Lera	NULL
T	NULL
,	NULL
Garcia-Diaz	NULL
M	NULL
,	NULL
Gonzalez	NULL
MA	NULL
,	NULL
Kirchhoff	NULL
T	NULL
,	NULL
Martinez-A	NULL
C	NULL
,	NULL
Bernad	NULL
A	NULL
,	NULL
Blanco	NULL
L.	NULL
DNA	NULL
polymerase	NULL
mu	NULL
(	NULL
Pol	NULL
u	NULL
)	NULL
,	NULL
homologous	NULL
to	NULL
TdT	NULL
,	NULL
could	NULL
act	NULL
as	NULL
a	NULL
DNA	NULL
mutator	NULL
in	NULL
eukaryotic	NULL
cells	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

2000	NULL
;	NULL
19:1731-1742	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10747040	NULL
]	NULL
Esposito	NULL
G	NULL
,	NULL
Godindagger	NULL
I	NULL
,	NULL
Klein	NULL
U	NULL
,	NULL
Yaspo	NULL
M	NULL
,	NULL
Cumano	NULL
A	NULL
,	NULL
Rajewsky	NULL
K.	NULL
Disruption	NULL
of	NULL
the	NULL
Rev3-encoded	NULL
catalytic	NULL
subunit	NULL
of	NULL
polymerase	NULL
zeta	NULL
in	NULL
mice	NULL
results	NULL
in	NULL
early	NULL
embryonic	NULL
lethality	NULL
.	NULL

Curr	NULL
.	NULL

Biol	NULL
.	NULL

2000a	NULL
;	NULL
10:1221-1224	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
11050393	NULL
]	NULL
Esposito	NULL
G	NULL
,	NULL
Texido	NULL
G	NULL
,	NULL
Betz	NULL
UA	NULL
,	NULL
Gu	NULL
H	NULL
,	NULL
Muller	NULL
W	NULL
,	NULL
Klein	NULL
U	NULL
,	NULL
Rajewsky	NULL
K.	NULL
Mice	NULL
reconstituted	NULL
with	NULL
DNA	NULL
polymerase	NULL
beta-deficient	NULL
fetal	NULL
liver	NULL
cells	NULL
are	NULL
able	NULL
to	NULL
mount	NULL
a	NULL
T	NULL
cell-dependent	NULL
immune	NULL
response	NULL
and	NULL
mutate	NULL
their	NULL
Ig	NULL
genes	NULL
normally	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

2000b	NULL
;	NULL
97:1	NULL
166-1171	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10655502	NULL
]	NULL
Faria	NULL
M	NULL
,	NULL
Wood	NULL
CD	NULL
,	NULL
Perrouault	NULL
L	NULL
,	NULL
Nelson	NULL
JS	NULL
,	NULL
Winter	NULL
A	NULL
,	NULL
White	NULL
MR	NULL
,	NULL
Helene	NULL
C	NULL
,	NULL
Giovannangeli	NULL
C.	NULL
Targeted	NULL
inhibition	NULL
of	NULL
transcription	NULL
elongation	NULL
in	NULL
cells	NULL
mediated	NULL
by	NULL
triplex-forming	NULL
oligonucleotides	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

2000	NULL
;	NULL
97:3862-3867	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10760257	NULL
]	NULL
Fukita	NULL
Y	NULL
,	NULL
Jacobs	NULL
H	NULL
,	NULL
Rajewsky	NULL
K.	NULL
Somatic	NULL
hypermutation	NULL
in	NULL
the	NULL
heavy	NULL
chain	NULL
locus	NULL
correlates	NULL
with	NULL
transcription	NULL
.	NULL

Immunity	NULL
.	NULL

1998	NULL
;	NULL
9:105-114	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9697840	NULL
]	NULL
Garcia-Diaz	NULL
M	NULL
,	NULL
Dominguez	NULL
O	NULL
,	NULL
Lopez-Fernandez	NULL
LA	NULL
,	NULL
de	NULL
Lera	NULL
LT	NULL
,	NULL
Saniger	NULL
ML	NULL
,	NULL
Ruiz	NULL
JF	NULL
,	NULL
Parraga	NULL
M	NULL
,	NULL
Garcia-Ortiz	NULL
MJ	NULL
,	NULL
Kirchhoff	NULL
T	NULL
,	NULL
del	NULL
Mazo	NULL
J	NULL
,	NULL
et	NULL
al	NULL
.	NULL

DNA	NULL
polymerase	NULL
lambda	NULL
(	NULL
Pol	NULL
lambda	NULL
)	NULL
,	NULL
a	NULL
novel	NULL
eukaryotic	NULL
DNA	NULL
polymerase	NULL
with	NULL
a	NULL
potential	NULL
role	NULL
in	NULL
meiosis	NULL
.	NULL

J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

2000	NULL
;	NULL
301:851-867	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10966791	NULL
]	NULL
Gewirtz	NULL
AM	NULL
,	NULL
Sokol	NULL
DL	NULL
,	NULL
Ratajezak	NULL
MZ	NULL
.	NULL

Nucleic	NULL
acid	NULL
therapeutics	NULL
:	NULL
state	NULL
of	NULL
the	NULL
art	NULL
and	NULL
future	NULL
prospects	NULL
.	NULL

Blood	NULL
.	NULL

1998	NULL
;	NULL
92:712-736	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9680338	NULL
]	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
13	NULL
Gibbs	NULL
PE	NULL
,	NULL
McGregor	NULL
WG	NULL
,	NULL
Maher	NULL
VM	NULL
,	NULL
Nisson	NULL
P	NULL
,	NULL
Lawrence	NULL
CW	NULL
.	NULL

A	NULL
human	NULL
homolog	NULL
of	NULL
the	NULL
Saccharomyces	NULL
cerevisiae	NULL
REV	NULL
3	NULL
gene	NULL
,	NULL
which	NULL
encodes	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
DNA	NULL
polymerase	NULL
zeta	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

1998	NULL
;	NULL
95:68	NULL
76-6880	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9618506	NULL
]	NULL
Gibbs	NULL
PE	NULL
,	NULL
Wang	NULL
XD	NULL
,	NULL
Li	NULL
Z	NULL
,	NULL
McManus	NULL
TP	NULL
,	NULL
McGregor	NULL
WG	NULL
,	NULL
Lawrence	NULL
CW	NULL
,	NULL
Maher	NULL
VM	NULL
.	NULL

The	NULL
function	NULL
of	NULL
the	NULL
human	NULL
homolog	NULL
of	NULL
Saccharomyces	NULL
cerevisiae	NULL
REV	NULL
1	NULL
is	NULL
required	NULL
for	NULL
mutagenesis	NULL
induced	NULL
by	NULL
UV	NULL
light	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

2000	NULL
;	NULL
97:4186-4191	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10760286	NULL
]	NULL
Haracska	NULL
L	NULL
,	NULL
Yu	NULL
SL	NULL
,	NULL
Johnson	NULL
RE	NULL
,	NULL
Prakash	NULL
L	NULL
,	NULL
Prakash	NULL
S.	NULL
Efficient	NULL
and	NULL
accurate	NULL
replication	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
7,8-dihydro-8-oxoguanine	NULL
by	NULL
DNA	NULL
polymerase	NULL
1	NULL
.	NULL

Nature	NULL
Genet	NULL
.	NULL

2000	NULL
;	NULL
25:458-461	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10932195	NULL
]	NULL
Holbeck	NULL
SL	NULL
,	NULL
Strathern	NULL
JN	NULL
.	NULL

A	NULL
role	NULL
for	NULL
REV3	NULL
in	NULL
mutagenesis	NULL
during	NULL
double-strand	NULL
break	NULL
repair	NULL
in	NULL
Saccharomyces	NULL
cerevisiae	NULL
.	NULL

Genetics	NULL
.	NULL

1997	NULL
;	NULL
147:1017-1024	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9383049	NULL
]	NULL
Tkematsu	NULL
H	NULL
,	NULL
Harindranath	NULL
N	NULL
,	NULL
Ueki	NULL
Y	NULL
,	NULL
Notkins	NULL
AL	NULL
,	NULL
Casali	NULL
P.	NULL
Clonal	NULL
analysis	NULL
of	NULL
a	NULL
human	NULL
antibody	NULL
response	NULL
.	NULL

II	NULL
.	NULL

Sequences	NULL
of	NULL
the	NULL
Vy	NULL
genes	NULL
of	NULL
human	NULL
monoclonal	NULL
IgM	NULL
,	NULL
IgG	NULL
and	NULL
IgA	NULL
to	NULL
rabies	NULL
virus	NULL
reveal	NULL
preferential	NULL
utilization	NULL
of	NULL
the	NULL
Vg3	NULL
segments	NULL
and	NULL
somatic	NULL
hypermutation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

1993	NULL
;	NULL
150:1325-1337	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8432980	NULL
]	NULL
Tkematsu	NULL
W	NULL
,	NULL
Kobarg	NULL
J	NULL
,	NULL
Ikematsu	NULL
H	NULL
,	NULL
Ichiyoshi	NULL
Y	NULL
,	NULL
Casali	NULL
P.	NULL
Clonal	NULL
analysis	NULL
of	NULL
a	NULL
human	NULL
antibody	NULL
response	NULL
.	NULL

III	NULL
.	NULL

Nucleotide	NULL
sequences	NULL
of	NULL
human	NULL
monoclonal	NULL
IgM	NULL
,	NULL
IgG	NULL
and	NULL
IgA	NULL
to	NULL
rabies	NULL
virus	NULL
reveal	NULL
Vx	NULL
gene	NULL
utilization	NULL
,	NULL
junctional	NULL
V-Jx	NULL
and	NULL
VA-JA	NULL
heterogeneity	NULL
,	NULL
and	NULL
somatic	NULL
hypermutation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

1998	NULL
;	NULL
161:2895-2905	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9743351	NULL
]	NULL
Johnson	NULL
RE	NULL
,	NULL
Washington	NULL
MT	NULL
,	NULL
Prakash	NULL
S	NULL
,	NULL
Prakash	NULL
L.	NULL
Bridging	NULL
the	NULL
gap	NULL
:	NULL
a	NULL
family	NULL
of	NULL
novel	NULL
DNA	NULL
polymerases	NULL
that	NULL
replicate	NULL
faulty	NULL
DNA	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

1999	NULL
;	NULL
96:12224-12226	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10535901	NULL
]	NULL
Johnson	NULL
RE	NULL
,	NULL
Kondratick	NULL
CM	NULL
,	NULL
Prakash	NULL
S	NULL
,	NULL
Prakash	NULL
L.	NULL
hRAD3O	NULL
mutations	NULL
in	NULL
the	NULL
variant	NULL
form	NULL
of	NULL
Xeroderma	NULL
pigmentosum	NULL
.	NULL

Science	NULL
.	NULL

19998	NULL
;	NULL
285:263-265	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10398605	NULL
]	NULL
Johnson	NULL
RE	NULL
,	NULL
Prakash	NULL
S	NULL
,	NULL
Prakash	NULL
L.	NULL
Efficient	NULL
bypass	NULL
of	NULL
a	NULL
thymine-thymine	NULL
dimer	NULL
by	NULL
yeast	NULL
DNA	NULL
polymerase	NULL
n.	NULL
Science	NULL
.	NULL

1999b	NULL
;	NULL
283:1001-1004	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9974380	NULL
]	NULL
Johnson	NULL
RE	NULL
,	NULL
Prakash	NULL
S	NULL
,	NULL
Prakash	NULL
L.	NULL
The	NULL
human	NULL
DINBI	NULL
gene	NULL
encodes	NULL
the	NULL
DNA	NULL
polymerase	NULL
0	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

20002	NULL
;	NULL
97:3838-3843	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10760255	NULL
]	NULL
Johnson	NULL
RE	NULL
,	NULL
Washington	NULL
MT	NULL
,	NULL
Haracska	NULL
L	NULL
,	NULL
Prakash	NULL
S	NULL
,	NULL
Prakash	NULL
L.	NULL
Eukaryotic	NULL
polymerases	NULL
t	NULL
and	NULL
&	NULL
act	NULL
sequentially	NULL
to	NULL
bypass	NULL
DNA	NULL
lesions	NULL
.	NULL

Nature	NULL
.	NULL

2000b	NULL
;	NULL
406:1015-1019	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10984059	NULL
]	NULL
Johnson	NULL
RE	NULL
,	NULL
Washington	NULL
MT	NULL
,	NULL
Prakash	NULL
S	NULL
,	NULL
Prakash	NULL
L.	NULL
Fidelity	NULL
of	NULL
human	NULL
DNA	NULL
polymerase	NULL
n.	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

2000c	NULL
;	NULL
275:7447-7450	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10713043	NULL
]	NULL
Lawrence	NULL
CW	NULL
,	NULL
Hinkle	NULL
DC	NULL
.	NULL

DNA	NULL
polymerase	NULL
zeta	NULL
and	NULL
the	NULL
control	NULL
of	NULL
DNA	NULL
damage	NULL
induced	NULL
mutagenesis	NULL
in	NULL
eukaryotes	NULL
.	NULL

Cancer	NULL
Surv	NULL
.	NULL

1996	NULL
;	NULL
28:21-31	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8977026	NULL
]	NULL
Lewis	NULL
JG	NULL
,	NULL
Lin	NULL
KY	NULL
,	NULL
Kothavale	NULL
A	NULL
,	NULL
Flanagan	NULL
WM	NULL
,	NULL
Matteucci	NULL
MD	NULL
,	NULL
DePrince	NULL
RB	NULL
,	NULL
Mook	NULL
RAJ	NULL
,	NULL
Hendren	NULL
RW	NULL
,	NULL
Wagner	NULL
RW	NULL
.	NULL

A	NULL
serum-resistant	NULL
cytofectin	NULL
for	NULL
cellular	NULL
delivery	NULL
of	NULL
anti-sense	NULL
oligodeoxynucleotides	NULL
and	NULL
plasmid	NULL
DNA	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

1996	NULL
;	NULL
93:3176-3181	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8622909	NULL
]	NULL
Lin	NULL
W	NULL
,	NULL
Hiachua	NULL
X	NULL
,	NULL
Wang	NULL
Z	NULL
.	NULL

A	NULL
full-length	NULL
cDNA	NULL
of	NULL
kREV3	NULL
is	NULL
predicted	NULL
to	NULL
encode	NULL
DNA	NULL
polymerase	NULL
&	NULL
for	NULL
damage-induced	NULL
mutagenesis	NULL
in	NULL
humans	NULL
.	NULL

Mutation	NULL
Research	NULL
.	NULL

1999	NULL
;	NULL
433:89-99	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10102035	NULL
]	NULL
Liu	NULL
YJ	NULL
,	NULL
de	NULL
Bouteiller	NULL
O	NULL
,	NULL
Arpin	NULL
C	NULL
,	NULL
Briere	NULL
F	NULL
,	NULL
Galibert	NULL
L	NULL
,	NULL
Ho	NULL
S	NULL
,	NULL
Martinez-Valdez	NULL
H	NULL
,	NULL
Banchereau	NULL
J	NULL
,	NULL
Lebecque	NULL
S.	NULL
Normal	NULL
human	NULL
IgD*IgM~-	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
can	NULL
express	NULL
up	NULL
to	NULL
80	NULL
mutations	NULL
in	NULL
the	NULL
variable	NULL
region	NULL
of	NULL
their	NULL
IgD	NULL
transcripts	NULL
.	NULL

Immunity	NULL
.	NULL

1996	NULL
;	NULL
4:603-613	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8673707	NULL
]	NULL
Masutani	NULL
C	NULL
,	NULL
Araki	NULL
M	NULL
,	NULL
Yamada	NULL
A	NULL
,	NULL
Kusumoto	NULL
R	NULL
,	NULL
Nagimori	NULL
T	NULL
,	NULL
Maekawa	NULL
T	NULL
,	NULL
Iwai	NULL
S	NULL
,	NULL
Hanaoka	NULL
F.	NULL
Xeroderma	NULL
pigmentosum	NULL
variant	NULL
(	NULL
XP-V	NULL
)	NULL
correcting	NULL
protein	NULL
from	NULL
HeLa	NULL
cells	NULL
has	NULL
a	NULL
thymidine	NULL
dimer	NULL
by	NULL
pass	NULL
DNA	NULL
polymerase	NULL
activity	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

19992	NULL
;	NULL
18:3491-3501	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10369688	NULL
]	NULL
Masutani	NULL
C	NULL
,	NULL
Kusumoto	NULL
R	NULL
,	NULL
Yamada	NULL
A	NULL
,	NULL
Dohamae	NULL
N	NULL
,	NULL
Yuasa	NULL
M	NULL
,	NULL
Araki	NULL
M	NULL
,	NULL
Iwai	NULL
S	NULL
,	NULL
Takio	NULL
K	NULL
,	NULL
Hanaoka	NULL
F.	NULL
The	NULL
XPV	NULL
(	NULL
xeroderma	NULL
pigmentosum	NULL
variant	NULL
)	NULL
gene	NULL
encodes	NULL
human	NULL
DNA	NULL
polymerase	NULL
1	NULL
.	NULL

Nature	NULL
.	NULL

1999b	NULL
;	NULL
399:700-704	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10385124	NULL
]	NULL
Masutani	NULL
C	NULL
,	NULL
Kusumoto	NULL
R	NULL
,	NULL
Iwai	NULL
S	NULL
,	NULL
Hanaoka	NULL
F.	NULL
Mechanisms	NULL
of	NULL
accurate	NULL
translesion	NULL
synthesis	NULL
by	NULL
human	NULL
DNA	NULL
polymerase	NULL
1	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

2000	NULL
;	NULL
19:3100-3109	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10856253	NULL
]	NULL
Matsuda	NULL
T	NULL
,	NULL
Bebenek	NULL
K	NULL
,	NULL
Masutani	NULL
C	NULL
,	NULL
Hanaoka	NULL
F	NULL
,	NULL
Kunkel	NULL
TA	NULL
.	NULL

Low	NULL
fidelity	NULL
DNA	NULL
synthesis	NULL
by	NULL
human	NULL
DNA	NULL
polymerase	NULL
1	NULL
.	NULL

Nature	NULL
.	NULL

2000	NULL
;	NULL
404:1011-1013	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10801132	NULL
]	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
14	NULL
McKean	NULL
D	NULL
,	NULL
Huppi	NULL
K	NULL
,	NULL
Bell	NULL
M	NULL
,	NULL
Staudt	NULL
L	NULL
,	NULL
Gerhard	NULL
W	NULL
,	NULL
Weigert	NULL
M.	NULL
Generation	NULL
of	NULL
antibody	NULL
diversity	NULL
in	NULL
the	NULL
immune	NULL
response	NULL
of	NULL
BALB/c	NULL
mice	NULL
to	NULL
influenza	NULL
virus	NULL
hemagglutinin	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

1984	NULL
;	NULL
81:3180-3184	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
6203114	NULL
]	NULL
Morrison	NULL
A	NULL
,	NULL
Christensen	NULL
RB	NULL
,	NULL
Alley	NULL
J	NULL
,	NULL
Beck	NULL
AK	NULL
,	NULL
Bernstine	NULL
EG	NULL
,	NULL
Lemontt	NULL
JF	NULL
,	NULL
Lawrence	NULL
CW	NULL
.	NULL

REV3	NULL
,	NULL
a	NULL
Saccharomyces	NULL
cerevisiae	NULL
gene	NULL
whose	NULL
function	NULL
is	NULL
required	NULL
for	NULL
induced	NULL
mutagenesis	NULL
,	NULL
is	NULL
predicted	NULL
to	NULL
encode	NULL
a	NULL
nonessential	NULL
DNA	NULL
polymerase	NULL
.	NULL

J.	NULL
Bacteriol	NULL
.	NULL

1989	NULL
;	NULL
171:5659-5667	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
2676986	NULL
]	NULL
Murakumo	NULL
Y	NULL
,	NULL
Roth	NULL
T	NULL
,	NULL
Ishii	NULL
H	NULL
,	NULL
Rasio	NULL
D	NULL
,	NULL
Numata	NULL
S	NULL
,	NULL
Croce	NULL
CM	NULL
,	NULL
Fishel	NULL
R.	NULL
A	NULL
human	NULL
REV7	NULL
homolog	NULL
that	NULL
interacts	NULL
with	NULL
the	NULL
polymerase	NULL
zeta	NULL
catalytic	NULL
subunit	NULL
hREV3	NULL
and	NULL
the	NULL
spindle	NULL
assembly	NULL
checkpoint	NULL
protein	NULL
hMAD2	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

2000	NULL
;	NULL
275:4391-4397	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10660610	NULL
]	NULL
Muramatsu	NULL
M	NULL
,	NULL
Kinoshita	NULL
K	NULL
,	NULL
Fagarasan	NULL
S	NULL
,	NULL
Yamada	NULL
S	NULL
,	NULL
Shinkai	NULL
Y	NULL
,	NULL
Honjo	NULL
T.	NULL
Class	NULL
switch	NULL
recombination	NULL
and	NULL
hypermutation	NULL
require	NULL
activation-induced	NULL
cytidine	NULL
deaminase	NULL
(	NULL
AID	NULL
)	NULL
,	NULL
a	NULL
potential	NULL
rna	NULL
editing	NULL
enzyme	NULL
.	NULL

Cell	NULL
.	NULL

2000	NULL
;	NULL
102:553-563	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
11007474	NULL
]	NULL
Nelson	NULL
JR	NULL
,	NULL
Lawrence	NULL
CW	NULL
,	NULL
Hinkle	NULL
DC	NULL
.	NULL

Thymine-thymine	NULL
dimer	NULL
bypass	NULL
by	NULL
yeast	NULL
DNA	NULL
polymerase	NULL
&	NULL
.	NULL

Science	NULL
.	NULL

1996	NULL
;	NULL
272:1646-1649	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8658138	NULL
]	NULL
Neuberger	NULL
MS	NULL
,	NULL
Ehrenstein	NULL
MR	NULL
,	NULL
Klix	NULL
N	NULL
,	NULL
Jolly	NULL
CJ	NULL
,	NULL
Yelamos	NULL
J	NULL
,	NULL
Rada	NULL
C	NULL
,	NULL
Milstein	NULL
C.	NULL
Monitoring	NULL
and	NULL
interpreting	NULL
the	NULL
intrinsic	NULL
features	NULL
of	NULL
somatic	NULL
hypermutation	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

1998	NULL
;	NULL
162:107-116	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9602357	NULL
]	NULL
Noguchi	NULL
,	NULL
PD	NULL
.	NULL

Use	NULL
of	NULL
flow	NULL
cytometry	NULL
for	NULL
DNA	NULL
analysis..	NULL

In	NULL
:	NULL
Coligan	NULL
,	NULL
JE	NULL
.	NULL

;	NULL
Kruisbeek	NULL
,	NULL
AM	NULL
.	NULL

;	NULL
Margulies	NULL
,	NULL
DV	NULL
.	NULL

;	NULL
Shevach	NULL
,	NULL
EM	NULL
.	NULL

,	NULL
editors	NULL
.	NULL

Current	NULL
Protocols	NULL
in	NULL
Immunology	NULL
.	NULL

W.	NULL
Strober	NULL
.	NULL

Greene	NULL
Publishing	NULL
Associates	NULL
and	NULL
Wiley-Interscience	NULL
;	NULL
New	NULL
York	NULL
:	NULL
1992.	NULL
p.	NULL
5.7.1-5.7.6	NULL
.	NULL

Ohashi	NULL
E	NULL
,	NULL
Ogi	NULL
T	NULL
,	NULL
Kusumoto	NULL
R	NULL
,	NULL
Iwai	NULL
S	NULL
,	NULL
Masutani	NULL
C	NULL
,	NULL
Hanaoka	NULL
F	NULL
,	NULL
Ohmori	NULL
H.	NULL
Error-prone	NULL
bypass	NULL
of	NULL
certain	NULL
DNA	NULL
lesions	NULL
by	NULL
the	NULL
human	NULL
DNA	NULL
polymerase	NULL
x	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

2000	NULL
;	NULL
14:1589-1594	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10887153	NULL
]	NULL
Papavasiliou	NULL
FN	NULL
,	NULL
Schatz	NULL
DG	NULL
.	NULL

Cell-cycle-regulated	NULL
DNA	NULL
double-stranded	NULL
breaks	NULL
in	NULL
somatic	NULL
hypermutation	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
.	NULL

Nature	NULL
.	NULL

2000	NULL
;	NULL
408:216-221	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
11089977	NULL
]	NULL
Pascual	NULL
V	NULL
,	NULL
Liu	NULL
YJ	NULL
,	NULL
Magalski	NULL
A	NULL
,	NULL
de	NULL
Bouteiller	NULL
O	NULL
,	NULL
Banchereau	NULL
J	NULL
,	NULL
Capra	NULL
JD	NULL
.	NULL

Analysis	NULL
of	NULL
somatic	NULL
mutation	NULL
in	NULL
five	NULL
B	NULL
cell	NULL
subsets	NULL
of	NULL
human	NULL
tonsil	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

1994	NULL
;	NULL
180:329-339	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8006591	NULL
]	NULL
Pasqualueci	NULL
L	NULL
,	NULL
Migliazza	NULL
A	NULL
,	NULL
Fracchiolla	NULL
N	NULL
,	NULL
William	NULL
C	NULL
,	NULL
Neri	NULL
A	NULL
,	NULL
Baldini	NULL
L	NULL
,	NULL
Chaganti	NULL
RSK	NULL
,	NULL
Klein	NULL
U	NULL
,	NULL
Kiippers	NULL
R	NULL
,	NULL
Rajewsky	NULL
K	NULL
,	NULL
Dalla-Favera	NULL
R.	NULL
BCL-6	NULL
mutations	NULL
in	NULL
normal	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
:	NULL
evidence	NULL
of	NULL
somatic	NULL
hypermutation	NULL
acting	NULL
outside	NULL
Ig	NULL
loci	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

1998	NULL
;	NULL
95:11816-11821	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9751748	NULL
]	NULL
Peters	NULL
A	NULL
,	NULL
Storb	NULL
U.	NULL
Somatic	NULL
hypermutation	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
is	NULL
linked	NULL
to	NULL
transcription	NULL
initiation	NULL
.	NULL

Immunity	NULL
.	NULL

1996	NULL
;	NULL
4:57-65	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8574852	NULL
]	NULL
Poltoratsky	NULL
V	NULL
,	NULL
Goodman	NULL
MF	NULL
,	NULL
Scharff	NULL
MD	NULL
.	NULL

Error-prone	NULL
candidates	NULL
vie	NULL
for	NULL
somatic	NULL
mutation	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

2000	NULL
;	NULL
192:27-30	NULL
.	NULL

Prasad	NULL
R	NULL
,	NULL
Singhal	NULL
RK	NULL
,	NULL
Srivastava	NULL
DK	NULL
,	NULL
Molina	NULL
JT	NULL
,	NULL
Tomkinson	NULL
AE	NULL
,	NULL
Wilson	NULL
SH	NULL
.	NULL

Specific	NULL
interaction	NULL
of	NULL
DNA	NULL
polymerase	NULL
and	NULL
DNA	NULL
ligase	NULL
I	NULL
in	NULL
a	NULL
multiprotein	NULL
base	NULL
excision	NULL
repair	NULL
complex	NULL
from	NULL
bovine	NULL
testis	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1996	NULL
;	NULL
271:16000-16007	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8663274	NULL
]	NULL
Praseuth	NULL
D	NULL
,	NULL
Guieysse	NULL
AL	NULL
,	NULL
Helene	NULL
C.	NULL
Triple	NULL
helix	NULL
formation	NULL
and	NULL
the	NULL
antigene	NULL
strategy	NULL
for	NULL
sequence-specific	NULL
control	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
.	NULL

1999	NULL
;	NULL
1489:181-206	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10807007	NULL
]	NULL
Rada	NULL
C	NULL
,	NULL
Ehrenstein	NULL
MR	NULL
,	NULL
Neuberger	NULL
MS	NULL
,	NULL
Milstein	NULL
C.	NULL
Hot	NULL
spot	NULL
focusing	NULL
of	NULL
somatic	NULL
hypermutation	NULL
in	NULL
MSH2-deficient	NULL
mice	NULL
suggests	NULL
two	NULL
stages	NULL
of	NULL
mutational	NULL
targeting	NULL
.	NULL

Immunity	NULL
.	NULL

1998	NULL
;	NULL
9:135-141	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9697843	NULL
]	NULL
Revy	NULL
P	NULL
,	NULL
Muto	NULL
T	NULL
,	NULL
Levy	NULL
Y	NULL
,	NULL
Geissmann	NULL
F	NULL
,	NULL
Plebani	NULL
A	NULL
,	NULL
Sanal	NULL
O	NULL
,	NULL
Catalan	NULL
N	NULL
,	NULL
Forveille	NULL
M	NULL
,	NULL
Dufoureq-Lagelouse	NULL
R	NULL
,	NULL
Gennery	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Activation-induced	NULL
cytidine	NULL
deaminase	NULL
(	NULL
AID	NULL
)	NULL
deficiency	NULL
causes	NULL
the	NULL
autosomal	NULL
recessive	NULL
form	NULL
of	NULL
the	NULL
hyper-IgM	NULL
syndrome	NULL
(	NULL
HIGM2	NULL
)	NULL
.	NULL

Cell	NULL
.	NULL

2000	NULL
;	NULL
102:565-575	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
11007475	NULL
]	NULL
Sale	NULL
JE	NULL
,	NULL
Neuberger	NULL
MS.	NULL
TdT-accessibe	NULL
breaks	NULL
are	NULL
scattered	NULL
over	NULL
the	NULL
immunoglobulin	NULL
V	NULL
domain	NULL
in	NULL
a	NULL
constitutively	NULL
hypermutating	NULL
B	NULL
cell	NULL
line	NULL
.	NULL

Immunity	NULL
.	NULL

1998	NULL
;	NULL
9:859-869	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9881976	NULL
]	NULL
Schaffer	NULL
A	NULL
,	NULL
Cerutti	NULL
A	NULL
,	NULL
Shah	NULL
S	NULL
,	NULL
Zan	NULL
H	NULL
,	NULL
Casali	NULL
P.	NULL
The	NULL
evolutionary	NULL
conserved	NULL
sequence	NULL
upstream	NULL
of	NULL
the	NULL
human	NULL
Ig	NULL
Sy3	NULL
region	NULL
is	NULL
an	NULL
inducible	NULL
promoter	NULL
:	NULL
synergistic	NULL
activation	NULL
by	NULL
CD40	NULL
ligand	NULL
and	NULL
IL-4	NULL
via	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
15	NULL
cooperative	NULL
NF-xB	NULL
and	NULL
STAT-6	NULL
binding	NULL
sites	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

1999	NULL
;	NULL
162:5327-5336	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10228008	NULL
]	NULL
Seidman	NULL
,	NULL
MM	NULL
.	NULL

Detection	NULL
and	NULL
characterization	NULL
of	NULL
mutations	NULL
in	NULL
mammalian	NULL
cells	NULL
with	NULL
the	NULL
pSP189	NULL
shuttle	NULL
vector	NULL
system..	NULL

In	NULL
:	NULL
Pfeifer	NULL
,	NULL
GP	NULL
.	NULL

,	NULL
editor	NULL
.	NULL

Technologies	NULL
for	NULL
Detection	NULL
of	NULL
DNA	NULL
Damage	NULL
and	NULL
Mutations	NULL
.	NULL

Plenum	NULL
Press	NULL
;	NULL
New	NULL
York	NULL
:	NULL
1996.	NULL
p.	NULL
373-390	NULL
.	NULL

Shannon	NULL
M	NULL
,	NULL
Weigert	NULL
M.	NULL
Fixing	NULL
mismatches	NULL
.	NULL

Science	NULL
.	NULL

1998	NULL
;	NULL
159-1160	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9508690	NULL
]	NULL
Shen	NULL
HM	NULL
,	NULL
Peters	NULL
A	NULL
,	NULL
Baron	NULL
B	NULL
,	NULL
Zhu	NULL
X	NULL
,	NULL
Storb	NULL
U.	NULL
Mutation	NULL
of	NULL
the	NULL
be/-6	NULL
gene	NULL
in	NULL
normal	NULL
B	NULL
cells	NULL
by	NULL
the	NULL
process	NULL
of	NULL
somatic	NULL
hypermutation	NULL
of	NULL
Ig	NULL
genes	NULL
.	NULL

Science	NULL
.	NULL

1998	NULL
;	NULL
280:1750-1752	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9624052	NULL
]	NULL
Smith	NULL
DS	NULL
,	NULL
Creadon	NULL
G	NULL
,	NULL
Jena	NULL
PK	NULL
,	NULL
Portanova	NULL
JP	NULL
,	NULL
Kotzin	NULL
BL	NULL
,	NULL
Wysocki	NULL
LJ	NULL
.	NULL

Di-	NULL
and	NULL
trinucleotide	NULL
target	NULL
preferences	NULL
of	NULL
somatic	NULL
mutagenesis	NULL
in	NULL
normal	NULL
and	NULL
autoreactive	NULL
B	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

1996	NULL
;	NULL
156:2642-2652	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8786330	NULL
]	NULL
Sobol	NULL
RW	NULL
,	NULL
Horton	NULL
JK	NULL
,	NULL
Kuhn	NULL
R	NULL
,	NULL
Gu	NULL
H	NULL
,	NULL
Singhal	NULL
RK	NULL
,	NULL
Prasad	NULL
R	NULL
,	NULL
Rajewsky	NULL
K	NULL
,	NULL
Wilson	NULL
SH	NULL
.	NULL

Requirement	NULL
of	NULL
mammalian	NULL
DNA	NULL
polymerase	NULL
beta	NULL
in	NULL
base-excision	NULL
repair	NULL
.	NULL

Nature	NULL
.	NULL

1996	NULL
;	NULL
379:183-186	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8538772	NULL
]	NULL
Storb	NULL
U	NULL
,	NULL
Klotz	NULL
EL	NULL
,	NULL
Hackett	NULL
JJ	NULL
,	NULL
Kage	NULL
K	NULL
,	NULL
Bozek	NULL
G	NULL
,	NULL
Martin	NULL
TE	NULL
.	NULL

A	NULL
hypermutable	NULL
insert	NULL
in	NULL
an	NULL
immunoglobulin	NULL
transgene	NULL
contains	NULL
hotspots	NULL
of	NULL
somatic	NULL
mutation	NULL
and	NULL
sequences	NULL
predicting	NULL
highly	NULL
stable	NULL
structures	NULL
in	NULL
the	NULL
RNA	NULL
transcript	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

1998a	NULL
;	NULL
188:689-698	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9705951	NULL
]	NULL
Storb	NULL
U	NULL
,	NULL
Peters	NULL
A	NULL
,	NULL
Klotz	NULL
E	NULL
,	NULL
Kim	NULL
N	NULL
,	NULL
Shen	NULL
HM	NULL
,	NULL
Kage	NULL
K	NULL
,	NULL
Rogerson	NULL
B	NULL
,	NULL
Martin	NULL
TE	NULL
.	NULL

Somatic	NULL
hypermutation	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
is	NULL
linked	NULL
to	NULL
transcription	NULL
.	NULL

Cur	NULL
.	NULL

Top	NULL
.	NULL

Microb	NULL
.	NULL

Immunol	NULL
.	NULL

1998c	NULL
;	NULL
229:11-20	NULL
.	NULL

Strathern	NULL
JN	NULL
,	NULL
Shafer	NULL
BK	NULL
,	NULL
McGill	NULL
CB	NULL
.	NULL

DNA	NULL
synthesis	NULL
errors	NULL
associated	NULL
with	NULL
double-strand-break	NULL
repair	NULL
.	NULL

Genetics	NULL
.	NULL

1995	NULL
;	NULL
140:965-972	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7672595	NULL
]	NULL
Tissier	NULL
A	NULL
,	NULL
McDonald	NULL
JP	NULL
,	NULL
Frank	NULL
EG	NULL
,	NULL
Woodgate	NULL
R.	NULL
pol	NULL
,	NULL
a	NULL
remarkably	NULL
error-prone	NULL
human	NULL
DNA	NULL
polymerase	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

2000	NULL
;	NULL
14:1642-1650	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10887158	NULL
]	NULL
Ueki	NULL
Y	NULL
,	NULL
Goldfarb	NULL
IS	NULL
,	NULL
Harindranath	NULL
N	NULL
,	NULL
Gore	NULL
M	NULL
,	NULL
Koprowski	NULL
H	NULL
,	NULL
Notkins	NULL
AL	NULL
,	NULL
Casali	NULL
P.	NULL
Clonal	NULL
analysis	NULL
of	NULL
a	NULL
human	NULL
antibody	NULL
response	NULL
.	NULL

Quantitation	NULL
of	NULL
precursors	NULL
of	NULL
antibody-producing	NULL
cells	NULL
and	NULL
generation	NULL
and	NULL
characterization	NULL
of	NULL
monoclonal	NULL
IgM	NULL
,	NULL
IgG	NULL
,	NULL
and	NULL
IgA	NULL
to	NULL
rabies	NULL
virus	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

1990	NULL
;	NULL
171:19-34	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
2153188	NULL
]	NULL
Washington	NULL
MT	NULL
,	NULL
Johnson	NULL
RE	NULL
,	NULL
Prakash	NULL
S	NULL
,	NULL
Prakash	NULL
L.	NULL
Fidelity	NULL
and	NULL
processivity	NULL
of	NULL
Saccharomyces	NULL
cerevisiae	NULL
DNA	NULL
polymerase	NULL
eta	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1999	NULL
;	NULL
274:36835-36838	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10601233	NULL
]	NULL
Weissbach	NULL
A	NULL
.	NULL

The	NULL
functional	NULL
roles	NULL
of	NULL
mammalian	NULL
DNA	NULL
polymerase	NULL
.	NULL

Arch	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

1979	NULL
;	NULL
198:386-396	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
117754	NULL
]	NULL
Wilson	NULL
PC	NULL
,	NULL
Wilson	NULL
K	NULL
,	NULL
Liu	NULL
YJ	NULL
,	NULL
Banchereau	NULL
J	NULL
,	NULL
Pascual	NULL
V	NULL
,	NULL
Capra	NULL
JD	NULL
.	NULL

Receptor	NULL
revision	NULL
of	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
variable	NULL
region	NULL
genes	NULL
in	NULL
normal	NULL
human	NULL
B	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

2000	NULL
;	NULL
91:1881-1894	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10839804	NULL
]	NULL
Yamada	NULL
A	NULL
,	NULL
Masutani	NULL
C	NULL
,	NULL
Iwai	NULL
S	NULL
,	NULL
Hanaoka	NULL
F.	NULL
Complementation	NULL
of	NULL
defective	NULL
translesion	NULL
synthesis	NULL
and	NULL
UV	NULL
light	NULL
sensitivity	NULL
in	NULL
Xeroderma	NULL
pigmentosum	NULL
variant	NULL
cells	NULL
by	NULL
human	NULL
and	NULL
mouse	NULL
DNA	NULL
polymerase	NULL
eta	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

2000	NULL
;	NULL
28:2473-2480	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10871396	NULL
]	NULL
Zan	NULL
H	NULL
,	NULL
Cerutti	NULL
A	NULL
,	NULL
Schaffer	NULL
A	NULL
,	NULL
Dramitinos	NULL
P	NULL
,	NULL
Casali	NULL
P.	NULL
CD40	NULL
engagement	NULL
triggers	NULL
switching	NULL
to	NULL
IgA1	NULL
and	NULL
Ig	NULL
A2	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
through	NULL
induction	NULL
of	NULL
endogenous	NULL
TGF-B	NULL
.	NULL

Evidence	NULL
for	NULL
TGF-	NULL
but	NULL
not	NULL
IL-10-dependent	NULL
direct	NULL
Su-Sa	NULL
and	NULL
sequential	NULL
Su-Sy	NULL
,	NULL
Sy-Sqa	NULL
DNA	NULL
recombination	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

1998	NULL
;	NULL
161:5217-5225	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9820493	NULL
]	NULL
Zan	NULL
H	NULL
,	NULL
Cerutti	NULL
A	NULL
,	NULL
Dramitinos	NULL
P	NULL
,	NULL
Schaffer	NULL
A	NULL
,	NULL
Li	NULL
Z	NULL
,	NULL
Casali	NULL
P.	NULL
Induction	NULL
of	NULL
Ig	NULL
somatic	NULL
hypermutation	NULL
and	NULL
class	NULL
switching	NULL
in	NULL
a	NULL
human	NULL
monoclonal	NULL
IgM	NULL
*	NULL
IgD*	NULL
cell	NULL
line	NULL
in	NULL
vitro	NULL
:	NULL
definition	NULL
of	NULL
the	NULL
requirements	NULL
and	NULL
the	NULL
modalities	NULL
of	NULL
hypermutation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

1999	NULL
;	NULL
162:3437-3447	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10092799	NULL
]	NULL
Zan	NULL
H	NULL
,	NULL
Li	NULL
Z	NULL
,	NULL
Yamaji	NULL
K	NULL
,	NULL
Dramitinos	NULL
P	NULL
,	NULL
Cerutti	NULL
A	NULL
,	NULL
Casali	NULL
P.	NULL
BCR	NULL
engagement	NULL
and	NULL
T	NULL
cell	NULL
contact	NULL
induce	NULL
bel-6	NULL
hypermutation	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
:	NULL
association	NULL
with	NULL
initiation	NULL
of	NULL
transcription	NULL
and	NULL
identity	NULL
with	NULL
Ig	NULL
hypermutation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

20003	NULL
;	NULL
165:830-839	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
10878357	NULL
]	NULL
Zan	NULL
H	NULL
,	NULL
Li	NULL
Z	NULL
,	NULL
Gurrien	NULL
C	NULL
,	NULL
Yamaji	NULL
K	NULL
,	NULL
Cerutti	NULL
A	NULL
,	NULL
Flajnik	NULL
MF	NULL
,	NULL
Diaz	NULL
M	NULL
,	NULL
Casali	NULL
P.	NULL
BCR-engagement	NULL
induces	NULL
downregulation	NULL
of	NULL
the	NULL
error-free	NULL
DNA	NULL
polymerase	NULL
1	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

Association	NULL
with	NULL
the	NULL
introduction	NULL
of	NULL
Ig	NULL
mutations	NULL
by	NULL
the	NULL
translesion	NULL
DNA	NULL
polymerase	NULL
&	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

2000	NULL
;	NULL
14	NULL
:	NULL
A1043	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
16	NULL
Tonsillar	NULL
B	NULL
cells	NULL
N	NULL
ECC	NULL
CC	NULL
M	NULL
N	NULL
EC	NULL
CC	NULL
M	NULL
pol	NULL
C	NULL
(	NULL
REV3	NULL
)	NULL
wee	NULL
sme	NULL
mm	NULL
|	NULL
900	NULL
bp	NULL
J	NULL
;	NULL
B-ACHT	NULL
!	NULL

|	NULL
wmuge	NULL
cmm	NULL
cme	NULL
cme	NULL
|	NULL
600	NULL
DD	NULL
pol	NULL
1	NULL
(	NULL
RAD3OA	NULL
)	NULL
|=-=	NULL
=	NULL
}	NULL
400	NULL
bp	NULL
pol	NULL
i	NULL
(	NULL
RAD3OB	NULL
)	NULL
|	NULL
--	NULL
_-	NULL
--	NULL
]	NULL
3	NULL
ig	NULL
pol	NULL
«	NULL
8	NULL
igo	NULL
pol	NULL
p	NULL
,	NULL
pol	NULL
6	NULL
-	NULL
,	NULL
pols	NULL
pol	NULL
k	NULL
[	NULL
ﬁ	NULL
j	NULL
|	NULL
f	NULL
--	NULL
-	NULL
pol	NULL
u	NULL
'man	NULL
[	NULL
-	NULL
<	NULL
-	NULL
-	NULL
-=	NULL
]	NULL
CD79b	NULL
[	NULL
(	NULL
--	NULL
--	NULL
--	NULL
--	NULL
]	NULL
j	NULL
V	NULL
,	NULL
,	NULL
DJ	NULL
,	NULL
CS	NULL
sume	NULL
______|	NULL
IgD	NULL
CD38	NULL
a	NULL
InrJ	NULL
m1	NULL
10°	NULL
m	NULL
}	NULL
m	NULL
“	NULL
Figure	NULL
1	NULL
.	NULL

Somatic	NULL
Hypermutating	NULL
Human	NULL
Tonsillar	NULL
B	NULL
Cells	NULL
Upregulate	NULL
DNA	NULL
pol	NULL
£	NULL
and	NULL
Downregulate	NULL
pol	NULL
1	NULL
Mutating	NULL
IgD*CD38*	NULL
early	NULL
centroblasts	NULL
(	NULL
EC	NULL
)	NULL
and	NULL
IgD~CD38*	NULL
centroblasts/centrocytes	NULL
(	NULL
CC	NULL
)	NULL
and	NULL
unmutating	NULL
IgD*CD38~	NULL
naive	NULL
(	NULL
N	NULL
)	NULL
and	NULL
IgD	NULL
CD38	NULL
,	NULL
memory	NULL
(	NULL
M	NULL
)	NULL
B	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
human	NULL
tonsillar	NULL
B	NULL
cells	NULL
and	NULL
analyzed	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
pol	NULL
£	NULL
REV3	NULL
,	NULL
pol	NULL
n	NULL
(	NULL
RAD3OA	NULL
)	NULL
,	NULL
pol	NULL
v	NULL
(	NULL
RAD3OB	NULL
)	NULL
,	NULL
pol	NULL
a	NULL
,	NULL
pol	NULL
B	NULL
,	NULL
pol	NULL
8	NULL
,	NULL
pol	NULL
s	NULL
,	NULL
pol	NULL
x	NULL
,	NULL
and	NULL
pol	NULL
u	NULL
,	NULL
using	NULL
RT-PCR	NULL
.	NULL

Pol	NULL
£	NULL
,	NULL
pol	NULL
n	NULL
,	NULL
and	NULL
B-actin	NULL
were	NULL
amplified	NULL
in	NULL
the	NULL
same	NULL
vessel	NULL
.	NULL

These	NULL
findings	NULL
were	NULL
derived	NULL
from	NULL
one	NULL
of	NULL
three	NULL
experiments	NULL
yielding	NULL
comparable	NULL
results	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
17	NULL
®	NULL
o	NULL
2.0	NULL
VDJp	NULL
;	NULL
mutation	NULL
frequency	NULL
(	NULL
change/base	NULL
x	NULL
104	NULL
)	NULL
o	NULL
O	NULL
Anti-BCR	NULL
Ab	NULL
_-	NULL
+	NULL
CD4*	NULL
T	NULL
cells	NULL
~	NULL
-	NULL
+	NULL
+	NULL
+	NULL
pol	NULL
t	NULL
(	NULL
REV3	NULL
)	NULL
|	NULL
-__-	NULL
=-	NULL
]	NULL
|	NULL
|	NULL
pol	NULL
n	NULL
(	NULL
RAD3OA	NULL
)	NULL
\	NULL
e	NULL
pol	NULL
i	NULL
(	NULL
RAD3OB	NULL
)	NULL
pol	NULL
a	NULL
|	NULL
wass	NULL
A	NULL
=	NULL
pon	NULL
(	NULL
--	NULL
-	NULL
po|6	NULL
-	NULL
Heth	NULL
-	NULL
pol	NULL
&	NULL
|	NULL
+-	NULL
‘	NULL
pol	NULL
|	NULL
|	NULL
B-actin	NULL
Figure	NULL
2	NULL
.	NULL

Upregulation	NULL
of	NULL
pol	NULL
{	NULL
and	NULL
Downregulation	NULL
of	NULL
pol	NULL
1	NULL
Are	NULL
Induced	NULL
by	NULL
BCR	NULL
Engagement	NULL
and	NULL
Are	NULL
Associated	NULL
with	NULL
Somatic	NULL
Hypermutation	NULL
Human	NULL
Ig	NULL
M*IgD*	NULL
CL-O1	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
with	NULL
or	NULL
without	NULL
treatment	NULL
with	NULL
anti-BCR	NULL
Ab	NULL
.	NULL

After	NULL
12	NULL
hr	NULL
,	NULL
1	NULL
,	NULL
2	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
and	NULL
9	NULL
days	NULL
,	NULL
0.5	NULL
x	NULL
10°	NULL
B	NULL
cells	NULL
from	NULL
each	NULL
culture	NULL
were	NULL
harvested	NULL
.	NULL

RNA	NULL
was	NULL
extracted	NULL
and	NULL
used	NULL
to	NULL
analyze	NULL
the	NULL
expression	NULL
level	NULL
of	NULL
pol	NULL
{	NULL
REV3	NULL
,	NULL
pol	NULL
11	NULL
,	NULL
pol	NULL
1	NULL
,	NULL
pol	NULL
a	NULL
,	NULL
pol	NULL
B	NULL
,	NULL
pol	NULL
8	NULL
,	NULL
pol	NULL
s	NULL
,	NULL
and	NULL
pol	NULL
u	NULL
by	NULL
RT-PCR	NULL
.	NULL

Shown	NULL
are	NULL
the	NULL
levels	NULL
of	NULL
the	NULL
DNA	NULL
polymerases	NULL
after	NULL
12	NULL
hr	NULL
of	NULL
culture	NULL
.	NULL

Comparable	NULL
levels	NULL
were	NULL
detected	NULL
at	NULL
day	NULL
1	NULL
,	NULL
2	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
and	NULL
9	NULL
.	NULL

After	NULL
14	NULL
days	NULL
,	NULL
the	NULL
cultures	NULL
were	NULL
terminated	NULL
to	NULL
identify	NULL
and	NULL
analyze	NULL
the	NULL
Ig	NULL
VygDJy	NULL
mutated	NULL
transcripts	NULL
.	NULL

Histograms	NULL
depict	NULL
the	NULL
findings	NULL
derived	NULL
from	NULL
one	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
yielding	NULL
comparable	NULL
results	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
18	NULL
A	NULL
6	NULL
nan-	NULL
-	NULL
>	NULL
h	NULL
pss	NULL
q	NULL
whim	NULL
“	NULL
0	NULL
01	NULL
0.2	NULL
04	NULL
0.8	NULL
1.6	NULL
32	NULL
64	NULL
hours	NULL
_	NULL
0	NULL
1°	NULL
3	NULL
60	NULL
9	NULL
240	NULL
48	NULL
pol	NULL
t	NULL
(	NULL
REV3	NULL
)	NULL
|	NULL
Suede	NULL
|	NULL
Series	NULL
|	NULL
pol	NULL
t	NULL
(	NULL
REV3	NULL
)	NULL
|	NULL
_-	NULL
fena	NULL
poln	NULL
(	NULL
RAD30A	NULL
)	NULL
’	NULL
-__	NULL
l	NULL
pol	NULL
n	NULL
‘	NULL
f	NULL
~~~	NULL
mame	NULL
]	NULL
pol	NULL
i	NULL
(	NULL
RAD3OB	NULL
)	NULL
F	NULL
_	NULL
ue	NULL
«	NULL
|	NULL
pol	NULL
i	NULL
DOW	NULL
,	NULL
”	NULL
-	NULL
'	NULL
cemu	NULL
cmm	NULL
~-|	NULL
B-actin	NULL
|	NULL
sew	NULL
meme	NULL
meme	NULL
meme	NULL
a	NULL
ie	NULL
pol	NULL
B	NULL
test	NULL
Huth	NULL
West	NULL
Ner	NULL
.	NULL

Stews	NULL
,	NULL
porate	NULL
\—	NULL
:	NULL
‘	NULL
D	NULL
Normal	NULL
IgM+IgD+	NULL
B	NULL
cells	NULL
polZ	NULL
‘	NULL
)	NULL
’	NULL
anti-BCR	NULL
Ab	NULL
s	NULL
pol	NULL
&	NULL
[	NULL
—	NULL
f	NULL
=|	NULL
pol	NULL
&	NULL
(	NULL
REV3	NULL
)	NULL
:	NULL
|	NULL
pol	NULL
u	NULL
{	NULL
—	NULL
mope	NULL
uses	NULL
Aummet	NULL
:	NULL
summ	NULL
_	NULL
J	NULL
pol	NULL
1	NULL
o	NULL
B-actin	NULL
i—A-	NULL
we	NULL
wasse	NULL
wus	NULL
wees	NULL
ae	NULL
‘	NULL
N	NULL
pol	NULL
1	NULL
pol	NULL
a	NULL
h	NULL
ﬂ	NULL
pol	NULL
&	NULL
(	NULL
REV3	NULL
)	NULL
eam	NULL
g	NULL
m=	NULL
W	NULL
po	NULL
.	NULL

1	NULL
|	NULL
B-actin	NULL
|	NULL
sneme	NULL
)	NULL
domed	NULL
iness	NULL
cmm	NULL
eme	NULL
}	NULL
wes	NULL
O	NULL
sysles	NULL
B-actin	NULL
e	NULL
o	NULL
m	NULL
pol	NULL
11	NULL
|	NULL
tual	NULL
-	NULL
tH	NULL
|	NULL
immeeth	NULL
|	NULL
|	NULL
.	NULL

«	NULL
o=	NULL
|	NULL
E	NULL
pol	NULL
&	NULL
(	NULL
REV3	NULL
)	NULL
|	NULL
wss	NULL
sume	NULL
U	NULL
A	NULL
ih	NULL
Aah	NULL
-	NULL
wes	NULL
Aah	NULL
Normal	NULL
CD4+*	NULL
T	NULL
cells	NULL
.	NULL

15	NULL
wat	NULL
a	NULL
pa.	NULL
G-actin	NULL
-	NULL
quails	NULL
duh	NULL
dumb	NULL
Auth	NULL
lath	NULL
|	NULL
sanke	NULL
pol	NULL
n	NULL
“	NULL
bu—u	NULL
...	NULL
-	NULL
—-	NULL
}	NULL
poIQ	NULL
(	NULL
REV3	NULL
)	NULL
‘	NULL
pol	NULL
C	NULL
(	NULL
REV3	NULL
)	NULL
-	NULL
s	NULL
-	NULL
sume	NULL
.	NULL

©	NULL
lh	NULL
tth	NULL
anes	NULL
amas	NULL
cams	NULL
pol	NULL
n	NULL
|	NULL
.	NULL

25	NULL
pol	NULL
i	NULL
B-actin	NULL
_-	NULL
ammap	NULL
aah	NULL
due	NULL
aad	NULL
pol	NULL
n	NULL
|	NULL
#	NULL
D	NULL
WHD	NULL
duet	NULL
weet	NULL
witt	NULL
sue	NULL
c	NULL
B-actin	NULL
*	NULL
%	NULL
Figure	NULL
3	NULL
.	NULL

Pol	NULL
{	NULL
Is	NULL
Upregulated	NULL
and	NULL
pol	NULL
n	NULL
Is	NULL
Downregulated	NULL
by	NULL
BCR	NULL
but	NULL
Not	NULL
TCR	NULL
in	NULL
a	NULL
Dose-	NULL
and	NULL
Time-Dependent	NULL
Fashion	NULL
in	NULL
Human	NULL
Lymphocytes	NULL
(	NULL
A	NULL
)	NULL
Human	NULL
CL-O01	NULL
cells	NULL
were	NULL
reacted	NULL
with	NULL
increasing	NULL
amounts	NULL
of	NULL
anti-BCR	NULL
Ab	NULL
for	NULL
1	NULL
hr	NULL
at	NULL
4°C	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
cultured	NULL
in	NULL
FCS-RPMI	NULL
for	NULL
12	NULL
hr	NULL
.	NULL

The	NULL
level	NULL
of	NULL
pol	NULL
&	NULL
REV3	NULL
,	NULL
pol	NULL
11	NULL
,	NULL
pol	NULL
1	NULL
,	NULL
pol	NULL
a	NULL
,	NULL
pol	NULL
B	NULL
,	NULL
pol	NULL
8	NULL
,	NULL
pol	NULL
g	NULL
,	NULL
and	NULL
pol	NULL
u	NULL
was	NULL
measured	NULL
by	NULL
RT-PCR	NULL
for	NULL
each	NULL
anti-BCR	NULL
Ab	NULL
concentration	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Level	NULL
of	NULL
pol	NULL
£	NULL
REV3	NULL
,	NULL
pol	NULL
n	NULL
,	NULL
and	NULL
B-actin	NULL
in	NULL
the	NULL
same	NULL
B	NULL
cells	NULL
as	NULL
in	NULL
(	NULL
A	NULL
)	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
single-vessel	NULL
RT-PCR	NULL
incorporating	NULL
[	NULL
a-P	NULL
]	NULL
dCTP	NULL
and	NULL
consisting	NULL
of	NULL
10	NULL
,	NULL
15	NULL
,	NULL
or	NULL
25	NULL
cycles	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Human	NULL
CL-O01	NULL
cells	NULL
were	NULL
reacted	NULL
with	NULL
anti-BCR	NULL
Ab	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
cultured	NULL
in	NULL
FCS-RPMI	NULL
.	NULL

The	NULL
level	NULL
of	NULL
pol	NULL
£	NULL
,	NULL
pol	NULL
1	NULL
,	NULL
and	NULL
pol	NULL
1	NULL
was	NULL
measured	NULL
at	NULL
1	NULL
,	NULL
3	NULL
,	NULL
6	NULL
,	NULL
9	NULL
,	NULL
24	NULL
,	NULL
and	NULL
48	NULL
hr	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Freshly	NULL
isolated	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
IgM	NULL
*IgD*	NULL
B	NULL
cells	NULL
were	NULL
reacted	NULL
with	NULL
anti-BCR	NULL
Ab	NULL
(	NULL
1	NULL
ug/ml	NULL
!	NULL
)	NULL

for	NULL
1	NULL
hr	NULL
at	NULL
4°C	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
cultured	NULL
in	NULL
FCS-RPMI	NULL
for	NULL
12	NULL
hr	NULL
before	NULL
analysis	NULL
of	NULL
pol	NULL
&	NULL
,	NULL
pol	NULL
n	NULL
,	NULL
and	NULL
pol	NULL
i	NULL
transcripts	NULL
.	NULL

(	NULL
E	NULL
)	NULL
Normal	NULL
human	NULL
CD4*	NULL
normal	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
FCS-RPMI	NULL
in	NULL
flat-bottom	NULL
96-well	NULL
culture	NULL
plates	NULL
coated	NULL
with	NULL
1:800	NULL
OKT3	NULL
anti-CD3	NULL
Ab	NULL
for	NULL
12	NULL
hr	NULL
and	NULL
then	NULL
analyzed	NULL
for	NULL
pol	NULL
&	NULL
,	NULL
pol	NULL
n	NULL
,	NULL
and	NULL
pol	NULL
i	NULL
transcripts	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

pol	NULL
n	NULL
(	NULL
RAD3OA	NULL
)	NULL
Page	NULL
19	NULL
A	NULL
C	NULL
VpDJp	NULL
pol	NULL
C	NULL
(	NULL
REV	NULL
3	NULL
)	NULL
__	NULL
|	NULL
«	NULL
--	NULL
=	NULL
4901	NULL
``	NULL
``	NULL
3°	NULL
3.0	NULL
O	NULL
e	NULL
S	NULL
O	NULL
§	NULL
[	NULL
|	NULL
polﬁ	NULL
C	NULL
O	NULL
r	NULL
g	NULL
0	NULL
T	NULL
_	NULL
iB	NULL
bel-6	NULL
>	NULL
poi	NULL
“	NULL
..	NULL
.	NULL

.	NULL

.	NULL

emscew	NULL
8	NULL
50	NULL
&	NULL
.	NULL

3	NULL
.	NULL

4.0	NULL
i	NULL
B-actin	NULL
93	NULL
--	NULL
3.0	NULL
.0	NULL
®	NULL
2.0	NULL
B	NULL
S	NULL
=	NULL
1.0	NULL
POI	NULL
G	NULL
(	NULL
REV	NULL
3	NULL
)	NULL
=	NULL
|wssuw	NULL
sums	NULL
maas	NULL
q	NULL
P	NULL
0	NULL
alll	NULL
Ld	NULL
F	NULL
pol	NULL
1	NULL
(	NULL
RAD3OA	NULL
)	NULL
_	NULL
w-	NULL
»	NULL
m	NULL
»	NULL
wos	NULL
cues	NULL
sel	NULL
,	NULL
,	NULL
2	NULL
E	NULL
pSP189	NULL
pol	NULL
1	NULL
(	NULL
RAD3OB	NULL
)	NULL
=	NULL
|	NULL
«	NULL
=	NULL
==	NULL
«	NULL
=	NULL
5	NULL
32	NULL
$	NULL
6	NULL
0	NULL
0	NULL
2	NULL
52.0	NULL
ll	NULL
-	NULL
===	NULL
!	NULL

sf	NULL
a	NULL
21.5	NULL
pol	NULL
B	NULL
|-—-—-——-~	NULL
tmms	NULL
.	NULL

mee	NULL
l	NULL
(	NULL
35	NULL
;	NULL
5	NULL
21.0	NULL
PO||J	NULL
|__—_——	NULL
‘	NULL
‘	NULL
géos	NULL
H	NULL
B-actin	NULL
_	NULL
|	NULL
|	NULL
€	NULL
5	NULL
|	NULL
ﬂ	NULL
Nil	NULL
SCRA	NULL
so1ASs01ASs02As03	NULL
Nil	NULL
SCRA	NULL
So1	NULL
ASo1	NULL
ASo2	NULL
ASos	NULL
Figure	NULL
4	NULL
.	NULL

Specific	NULL
Inhibition	NULL
of	NULL
pol	NULL
¢	NULL
REV3	NULL
Expression	NULL
Impairs	NULL
Ig	NULL
VyDJy	NULL
and	NULL
bel-6	NULL
Somatic	NULL
Hypermutation	NULL
as	NULL
well	NULL
as	NULL
Damage-Induced	NULL
DNA	NULL
Mutagenesis	NULL
in	NULL
CL-01	NULL
Cells	NULL
Induced	NULL
by	NULL
BCR	NULL
Engagement	NULL
and	NULL
Contact	NULL
with	NULL
Activated	NULL
CD4*	NULL
T	NULL
Cells	NULL
(	NULL
A	NULL
)	NULL
Human	NULL
B	NULL
cells	NULL
cocultured	NULL
with	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
upon	NULL
BCR	NULL
engagement	NULL
after	NULL
daily	NULL
treatment	NULL
with	NULL
Cytofectin	NULL
GSV	NULL
only	NULL
(	NULL
Nil	NULL
)	NULL
or	NULL
Cytofectin	NULL
GSV	NULL
together	NULL
with	NULL
the	NULL
specific	NULL
pol	NULL
{	NULL
REV3	NULL
$	NULL
01	NULL
,	NULL
AS01	NULL
,	NULL
AS02	NULL
,	NULL
AS03	NULL
,	NULL
or	NULL
SCRA	NULL
control	NULL
oligonucleotide	NULL
,	NULL
from	NULL
day	NULL
-1	NULL
to	NULL
day	NULL
13	NULL
.	NULL

B	NULL
cells	NULL
were	NULL
harvested	NULL
at	NULL
days	NULL
1	NULL
,	NULL
2	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
9	NULL
,	NULL
and	NULL
14	NULL
by	NULL
positive	NULL
selection	NULL
with	NULL
a	NULL
biotinylated	NULL
anti-CD19	NULL
mAb	NULL
and	NULL
MiniMac	NULL
System	NULL
Streptavidin	NULL
microbeads	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
,	NULL
Inc.	NULL
)	NULL
for	NULL
RNA	NULL
extraction	NULL
.	NULL

Shown	NULL
are	NULL
the	NULL
transcript	NULL
levels	NULL
of	NULL
pol	NULL
£	NULL
REV3	NULL
,	NULL
pol	NULL
1	NULL
,	NULL
pol	NULL
i	NULL
,	NULL
pol	NULL
a	NULL
,	NULL
pol	NULL
,	NULL
and	NULL
pol	NULL
u	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
RT-PCR	NULL
after	NULL
9	NULL
days	NULL
of	NULL
cultures	NULL
(	NULL
comparable	NULL
pol	NULL
{	NULL
inhibition	NULL
was	NULL
observed	NULL
at	NULL
all	NULL
other	NULL
time	NULL
points	NULL
analyzed	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
were	NULL
derived	NULL
from	NULL
one	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
yielding	NULL
comparable	NULL
results	NULL
(	NULL
data	NULL
are	NULL
from	NULL
the	NULL
experiments	NULL
of	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Specific	NULL
pol	NULL
£	NULL
REV3	NULL
oligonucleotides	NULL
selectively	NULL
inhibit	NULL
the	NULL
expression	NULL
of	NULL
pol	NULL
&	NULL
REV3	NULL
in	NULL
CL-O01	NULL
cells	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
and	NULL
without	NULL
prior	NULL
BCR	NULL
engagement	NULL
.	NULL

All	NULL
other	NULL
experimental	NULL
conditions	NULL
and	NULL
analyses	NULL
are	NULL
as	NULL
in	NULL
(	NULL
A	NULL
)	NULL
.	NULL

(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
Frequency	NULL
of	NULL
the	NULL
mutations	NULL
in	NULL
the	NULL
Ig	NULL
VyDJy	NULL
and	NULL
be/-6	NULL
transcripts	NULL
in	NULL
the	NULL
B	NULL
cells	NULL
from	NULL
the	NULL
cultures	NULL
of	NULL
(	NULL
A	NULL
)	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
20	NULL
(	NULL
E	NULL
)	NULL
CL-O1	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
Cytofectin	NULL
GSV	NULL
only	NULL
or	NULL
Cytofectin	NULL
GSV	NULL
together	NULL
with	NULL
the	NULL
pol	NULL
{	NULL
REV3	NULL
$	NULL
01	NULL
,	NULL
AS01	NULL
,	NULL
SCRA	NULL
,	NULL
ASO02	NULL
,	NULL
or	NULL
AS03	NULL
oligonucleotides	NULL
and	NULL
then	NULL
analyzed	NULL
for	NULL
the	NULL
damage-induced	NULL
mutagenesis	NULL
using	NULL
the	NULL
UV-treated	NULL
pSP189	NULL
shuttle	NULL
vector	NULL
.	NULL

Histograms	NULL
depict	NULL
the	NULL
frequency	NULL
of	NULL
6-thioguanine-resistant	NULL
mutants	NULL
(	NULL
white	NULL
colonies	NULL
out	NULL
of	NULL
about	NULL
4000	NULL
total	NULL
colonies	NULL
for	NULL
each	NULL
treatment	NULL
)	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Cell	NULL
growth	NULL
(	NULL
folds	NULL
)	NULL
100	NULL
10	NULL
-	NULL
@	NULL
-	NULL
medium	NULL
alone	NULL
--	NULL
SRA	NULL
-x-	NULL
sot	NULL
-x-	NULL
asot	NULL
-f-	NULL
cytofectin	NULL
only	NULL
(	NULL
nil	NULL
)	NULL
0	NULL
2	NULL
4	NULL
6	NULL
8	NULL
10	NULL
12	NULL
Culture	NULL
time	NULL
(	NULL
day	NULL
)	NULL
14	NULL
Nil	NULL
SCRA	NULL
Cell	NULL
Count	NULL
son	NULL
|	NULL
Asot	NULL
<	NULL
]	NULL
Page	NULL
21	NULL
Cellular	NULL
DNA	NULL
content	NULL
Figure	NULL
5	NULL
.	NULL

Cytofectin	NULL
GSV	NULL
and	NULL
the	NULL
pol	NULL
{	NULL
REV3	NULL
Phosphorothioate	NULL
Oligonucleotides	NULL
Do	NULL
Not	NULL
Significantly	NULL
Affect	NULL
B	NULL
Cell	NULL
Cycle	NULL
or	NULL
Proliferation	NULL
(	NULL
A	NULL
)	NULL
CD19*	NULL
cells	NULL
from	NULL
CL-O1	NULL
cultures	NULL
(	NULL
same	NULL
or	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
Figure	NULL
4	NULL
)	NULL
treated	NULL
daily	NULL
with	NULL
Nil	NULL
,	NULL
Cytofectin	NULL
GSV	NULL
only	NULL
,	NULL
and	NULL
Cytofectin	NULL
GSV	NULL
together	NULL
with	NULL
the	NULL
SCRA	NULL
,	NULL
S01	NULL
,	NULL
or	NULL
ASO1	NULL
oligonucleotides	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
harvested	NULL
for	NULL
counting	NULL
and	NULL
analysis	NULL
of	NULL
viability	NULL
at	NULL
days	NULL
0	NULL
,	NULL
1	NULL
,	NULL
2	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
9	NULL
,	NULL
and	NULL
14	NULL
of	NULL
culture	NULL
.	NULL

More	NULL
than	NULL
90	NULL
%	NULL
of	NULL
the	NULL
B	NULL
cells	NULL
were	NULL
viable	NULL
at	NULL
any	NULL
time	NULL
point	NULL
.	NULL

(	NULL
B	NULL
)	NULL
B	NULL
cell	NULL
(	NULL
from	NULL
[	NULL
A	NULL
]	NULL
)	NULL
cycle	NULL
analysis	NULL
by	NULL
PI	NULL
staining	NULL
at	NULL
days	NULL
0	NULL
,	NULL
2	NULL
,	NULL
7	NULL
,	NULL
9	NULL
,	NULL
and	NULL
14	NULL
of	NULL
culture	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04	NULL
.	NULL

Page	NULL
22	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Author	NULL
Manuscript	NULL
'osuospue	NULL
(	NULL
gy	NULL
f'osuss	NULL
'	NULL
g	NULL
'porquuess	NULL
'yyrog	NULL
'suop	NULL
j0U	NULL
``	NULL
(	NULL
IN	NULL
IF6	NULL
SFOL	NULL
-	NULL
08	NULL
%	NULL
6	NULL
PEOL	NULL
_	NULL
8FP€E	NULL
86t¢	NULL
-	NULL
FTC	NULL
PEE	NULL
-	NULL
7T9	NULL
%	NULL
6	NULL
I€TL	NULL
-	NULL
926	NULL
8S6TT	NULL
-	NULL
(	NULL
%	NULL
)	NULL
paempy	NULL
61	NULL
IT	NULL
OT	NULL
IT	NULL
8	NULL
€T	NULL
8	NULL
€T	NULL
(	NULL
x4	NULL
95	NULL
67	NULL
LS	NULL
pasmp	NULL
ZOT	NULL
107	NULL
POT	NULL
E07	NULL
OET	NULL
197	NULL
SSC	NULL
68€	NULL
6€T	NULL
SSP	NULL
LBT	NULL
6Et	NULL
pozkreuy	NULL
I9°.L	NULL
OT	NULL
IT	NULL
IT	NULL
IT	NULL
t	NULL
5	NULL
t	NULL
t	NULL
II	NULL
8C	NULL
LI	NULL
TI	NULL
pasmnp	NULL
OOT	NULL
IOT	NULL
ZOT	NULL
OOT	NULL
811	NULL
LET	NULL
EPI	NULL
OST	NULL
611	NULL
SPC	NULL
S81	NULL
601	NULL
pozkreuy	NULL
¢	NULL
juownadxg	NULL
6	NULL
OT	NULL
6	NULL
OT	NULL
P	NULL
8	NULL
P	NULL
9	NULL
TI	NULL
ST	NULL
TI	NULL
I6	NULL
posmp	NULL
TOT	NULL
OOT	NULL
TOT	NULL
€01	NULL
TH	NULL
PCT	NULL
TH	NULL
IET	NULL
ral	NULL
IOT	NULL
TH	NULL
TOC	NULL
pozkreuy	NULL
7	NULL
wounadxg	NULL
CN	NULL
CN	NULL
CN	NULL
CN	NULL
CN	NULL
CN	NULL
CN	NULL
€	NULL
CN	NULL
€T	NULL
CN	NULL
2	NULL
pasmnp	NULL
CN	NULL
CN	NULL
CN	NULL
CN	NULL
CN	NULL
CN	NULL
CN	NULL
801	NULL
CN	NULL
601	NULL
CN	NULL
SCI	NULL
pozkreuy	NULL
1	NULL
juowpadxg	NULL
#	NULL
704	NULL
0	NULL
``	NULL
ra	NULL
``	NULL
a	NULL
s	NULL
o	NULL
org	NULL
``	NULL
rara	NULL
oreo	NULL
org	NULL
.	NULL

o	NULL
org	NULL
``	NULL
roa	NULL
sdposue1y	NULL
,	NULL
EOSV	NULL
TOSV	NULL
IOSV	NULL
IOS	NULL
vos	NULL
TIN	NULL
uogemuwad	NULL
{	NULL
p	NULL
apewog	NULL
9-729	NULL
pue	NULL
HrqHa	NULL
81	NULL
soonpay	NULL
uotssoidxq	NULL
(	NULL
£473	NULL
)	NULL
9	NULL
asesour4jog	NULL
;	NULL
o	NULL
uonrqrqyuy	NULL
L	NULL
@	NULL
1qeL	NULL
Author	NULL
Manuscript	NULL
Author	NULL
Manuscript	NULL
Author	NULL
Manuscript	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04.	NULL
iduosnuep	NULL
1ouyuny	NULL
iduosnuep	NULL
1ouyiny	NULL
iduosnuep	NULL
iduosnuep	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

Table	NULL
2	NULL
Page	NULL
23	NULL
Nature	NULL
of	NULL
the	NULL
Base	NULL
Substitutions	NULL
in	NULL
the	NULL
Ig	NULL
VgDJy	NULL
and	NULL
be/-6	NULL
Genes	NULL
of	NULL
Induced	NULL
CL-O1	NULL
Cells	NULL
Transfected	NULL
by	NULL
DNA	NULL
Polymerase	NULL
Oligonucleotides	NULL
B	NULL
Cells	NULL
Transfected	NULL
by	NULL
DNA	NULL
Polymerase	NULL
Oligonucleotide	NULL
Transitions	NULL
G-C	NULL
A	NULL
-+	NULL
G	NULL
C-	NULL
T	NULL
T-+C	NULL
55	NULL
299	NULL
5	NULL
17	NULL
4	NULL
[	NULL
28.3	NULL
]	NULL
[	NULL
8.3	NULL
]	NULL
b	NULL
[	NULL
6.8	NULL
]	NULL
[	NULL
6.8	NULL
]	NULL
[	NULL
6.2	NULL
]	NULL
Transversions	NULL
G-C	NULL
A	NULL
-T	NULL
C	NULL
-	NULL
>	NULL
A	NULL
T	NULL
-+	NULL
A	NULL
11	NULL
5	NULL
1	NULL
4	NULL
1	NULL
[	NULL
28.3	NULL
]	NULL
[	NULL
8.2	NULL
]	NULL
[	NULL
6.8	NULL
]	NULL
6.8	NULL
]	NULL
[	NULL
6.2	NULL
]	NULL
G-T	NULL
A-	NULL
T	NULL
C-G	NULL
T-+G	NULL
19	NULL
8	NULL
5	NULL
0	NULL
6	NULL
[	NULL
28.3	NULL
]	NULL
[	NULL
8.3	NULL
]	NULL
[	NULL
6.8	NULL
]	NULL
[	NULL
6.8	NULL
]	NULL
[	NULL
6.2	NULL
]	NULL
Total	NULL
Mutations	NULL
G-+N	NULL
A	NULL
-+	NULL
N	NULL
C	NULL
-N	NULL
T	NULL
-+N	NULL
85	NULL
42d	NULL
11d	NULL
21	NULL
11°	NULL
[	NULL
85	NULL
]	NULL
[	NULL
25.0	NULL
]	NULL
[	NULL
20.5	NULL
]	NULL
[	NULL
20.5	NULL
]	NULL
[	NULL
18.7	NULL
]	NULL
B	NULL
Cells	NULL
Transfected	NULL
by	NULL
DNA	NULL
Polymerase	NULL
(	NULL
REV3	NULL
)	NULL
-	NULL
Specific	NULL
Oligonucleotide	NULL
Transitions	NULL
G-	NULL
A	NULL
A	NULL
-+	NULL
G	NULL
C-	NULL
T	NULL
T-+C	NULL
29	NULL
17	NULL
2	NULL
7	NULL
3	NULL
[	NULL
14.3	NULL
]	NULL
[	NULL
4.2	NULL
]	NULL
[	NULL
3.5	NULL
]	NULL
[	NULL
3.5	NULL
]	NULL
[	NULL
3.2	NULL
]	NULL
Transversions	NULL
G-C	NULL
A-+C	NULL
C	NULL
-	NULL
>	NULL
A	NULL
T	NULL
-+	NULL
A	NULL
7	NULL
2	NULL
2	NULL
2	NULL
1	NULL
[	NULL
14.3	NULL
]	NULL
[	NULL
4.2	NULL
]	NULL
[	NULL
3.5	NULL
]	NULL
[	NULL
3.5	NULL
]	NULL
[	NULL
3.2	NULL
]	NULL
G-T	NULL
A-	NULL
T	NULL
C-G	NULL
T-+G	NULL
7	NULL
3	NULL
0	NULL
1	NULL
3	NULL
[	NULL
14.3	NULL
]	NULL
[	NULL
4.2	NULL
]	NULL
[	NULL
3.5	NULL
]	NULL
[	NULL
3.5	NULL
]	NULL
[	NULL
3.2	NULL
]	NULL
Total	NULL
Mutations	NULL
G-+N	NULL
A	NULL
-+	NULL
N	NULL
C	NULL
-N	NULL
T	NULL
-+N	NULL
43	NULL
22d	NULL
4d	NULL
10	NULL
7	NULL
[	NULL
43	NULL
]	NULL
[	NULL
12.6	NULL
]	NULL
[	NULL
10.5	NULL
]	NULL
[	NULL
10.4	NULL
]	NULL
[	NULL
9.51	NULL
Identical	NULL
mutations	NULL
in	NULL
different	NULL
gene	NULL
segments	NULL
of	NULL
the	NULL
given	NULL
region	NULL
were	NULL
assumed	NULL
not	NULL
to	NULL
be	NULL
independent	NULL
and	NULL
were	NULL
counted	NULL
only	NULL
once	NULL
.	NULL

The	NULL
expected	NULL
number	NULL
of	NULL
mutations	NULL
(	NULL
from	NULL
a	NULL
given	NULL
nucleotide	NULL
residue	NULL
to	NULL
another	NULL
given	NULL
nucleotide	NULL
residue	NULL
)	NULL
was	NULL
normalized	NULL
for	NULL
the	NULL
base	NULL
composition	NULL
of	NULL
the	NULL
unmutated	NULL
Ig	NULL
VHDJH	NULL
and	NULL
be	NULL
!	NULL

-	NULL
>	NULL
6	NULL
gene	NULL
sequences	NULL
(	NULL
unstimulated	NULL
CL	NULL
-	NULL
>	NULL
01	NULL
cells	NULL
)	NULL
.	NULL

It	NULL
was	NULL
calculated	NULL
by	NULL
multiplying	NULL
the	NULL
frequency	NULL
of	NULL
occurrence	NULL
of	NULL
the	NULL
nucleotide	NULL
target	NULL
of	NULL
mutated	NULL
sequence	NULL
by	NULL
the	NULL
total	NULL
number	NULL
of	NULL
observed	NULL
mutations	NULL
and	NULL
dividing	NULL
the	NULL
product	NULL
by	NULL
three	NULL
.	NULL

p	NULL
<	NULL
0.05	NULL
.	NULL

d	NULL
p	NULL
<	NULL
0.001	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
November	NULL
04	NULL
.	NULL

